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Vitiligo is an autoimmune skin disease in which the pigment producing cells of the 
epidermis, melanocytes, are targeted for destruction by CD8+ T cells specific for 
melanocyte/melanoma-shared antigens. Previous work has identified IFNγ as the central 
cytokine driving disease pathogenesis in both human patients and in our mouse model of 
vitiligo. IFNγ signaling induces production of the chemokines CXCL9 and CXCL10, 
which trigger autoreactive T cell migration into the epidermis where effector T cells can 
target and destroy melanocytes. However, both IFNγ and type I IFN signaling through 
activation of STAT1 proteins can induce transcription of the chemokines CXCL9 and 
CXCL10. Therefore, it seems reasonable that type I IFN signaling may also contribute to 
disease pathogenesis. 
 
The role of type I IFN in vitiligo is still unclear. Genome wide association studies 
identified multiple genes within the type I IFN pathway including TICAM1 and IFIH1 as 
susceptibility loci in vitiligo. One additional study reported increased epidermal staining 
of CD123, a marker expressed by pDCs, and the type I IFN induced gene MX1 in vitiligo 
patient skin. However, this study did not show any functional data to support the role of 
type I IFN signaling in vitiligo pathogenesis. Since the role of type I IFN in vitiligo is ill-
defined, we used two different mouse models of vitiligo to functionally determine the 
role of type I IFN in disease by inducing vitiligo in hosts which lack the type I IFN 
receptor (IFNaR).  
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In the first model, we induced vitiligo by adoptive transfer of melanocyte-specific CD8 T 
cells, which are activated in vivo by infection with recombinant vaccinia virus (VACV) 
expressing their cognate antigen. Vitiligo induction in IFNaR-deficient mice led to the 
development of severe disease compared to wild type mice. Acceleration and severity of 
disease was characterized by increased early recruitment of melanocyte-specific CD8 T 
cells to the skin, increased production of effector cytokines TNFα and IFNγ, and reduced 
PD-1 expression. Increased production of IFNγ by CD8 T cells in the skin of IFNaR-
deficient mice led to increased expression of the chemokines CXCL9 and CXCL10 
driving disease progression. IFNaR-deficient mice also displayed significantly increased 
VACV titters compared to wild type hosts. This data reveals a role of type I IFN in the 
clearance of recombinant VACV. This data also suggests that persistent VACV infection 
and prolonged antigen exposure in IFNaR deficient hosts is likely driving enhanced 
activation of melanocyte specific CD8 T cells and the subsequent development of severe 
vitiligo.   
Since melanocytes and melanoma cells express shared antigens that can be recognized by 
CD8 T cells, and because the development of vitiligo after melanoma immunotherapy is a 
positive prognostic factor for patients, we asked whether VACV vaccine therapy in 
IFNaR deficient mice would enhance the anti-tumor response to melanoma. B16-F10 
inoculated wild type and IFNaR-deficient mice received adoptive transfer of melanocyte-
specific CD8 T cells in combination with vaccinia virus expressing their cognate antigen 
to activate the cells in vivo. Treatment of adoptive T cell transfer and infection with 
VACV in IFNAR-deficient mice revealed significantly reduced tumor burden compared 
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to wild type mice. Improved tumor regression in IFNaR-deficient hosts was characterized 
by increased infiltrating cytotoxic T lymphocytes and reduced PD-1 expression. These 
results further demonstrate that in the absence of type I IFN, hosts mount a robust 
cytotoxic CD8 T cell response against melanocyte/melanoma antigens and this is likely a 
result of persistent VACV that leads to prolonged CD8 T cell priming. As a result, IFNaR 
deficient hosts kill tumor cells more efficiently.  
To determine whether type I IFN regulates disease pathogenesis in the absence of virus 
infection, we generated a model of vitiligo in which bone marrow derived dendritic cells 
(BMDCs) pulsed with the cognate antigen were used to prime melanocyte-specific T 
cells in place of the viral vector. Induction of vitiligo in IFNaR-deficient hosts using 
BMDCs revealed no significant differences in disease score compared to wild type hosts. 
This data clearly demonstrates that type I IFN, in contrast to IFNγ, is not required during 
the effector stage of vitiligo pathogenesis in mice. 
However, since we intentionally activate transferred melanocyte-specific CD8 T cells 
with VACV or BMDCs expressing their cognate antigen, our mouse models may 
circumvent the role of type I IFNs in initiating activation of autoreactive cells and driving 
autoimmunity. Type I IFN is critical for providing innate immune signals that drive the 
priming of autoreactive T cells through maturation of DCs by inducing antigen 
presentation, co-stimulatory molecule expression, and migration to the lymph nodes to 
encounter naïve T cells. Our mouse models of vitiligo may not capture this process. We 
have addressed this question by using a TLR ligand to activate BMDCs before transfer 
into hosts. In fact, activation of BMDCs before transfer leads to significantly enhanced 
	 ix	
vitiligo in mice and this is partially a result of type I IFN signaling on host cells. Thus, we 
provide evidence that type I IFNs can enhance the activation of melanocyte-specific CD8 
T cells and drive autoimmunity.  
 
Collectively, our results show that type I IFN signaling has disparate effects on 
autoreactive T cell priming in a context dependent manner. We reveal that although type 
I IFN is not required for the effector phase of vitiligo in mice, maturation of DCs and 
subsequent type I IFN production can enhance the priming of autoreactive T cells and 
enhance vitiligo severity. Our studies also reveal that type I IFN is required to clear 
recombinant attenuated VACV infection and vaccine administration in IFNaR deficient 
hosts led to a robust autoreactive and anti-tumor response. These insights describing the 
role of type I IFN in autoimmunity and tumor immunology could have important 
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PREFACE TO CHAPTER 1 
 
Chapter 1, which serves as the Introduction to the dissertation, includes new and original 
text written by Rebecca L. Riding that is incorporated with text from the manuscripts 
cited below. “Mouse Model for Human Vitiligo” was written by Rebecca L. Riding and 
edited by Jillian M. Richmond and Dr. John E. Harris. Figures were composed by 
Rebecca L. Riding and Jillian M. Richmond. “The Role of Memory CD8 T cells in 
Vitiligo” was written by Rebecca L. Riding and edited by Dr. John E. Harris.  
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CHAPTER 1: INTRODUCTION 
 
1.1: Global impact of vitiligo 
 
Vitiligo is an autoimmune skin disease in which the the pigment producing cells of the 
epidermis, melanocytes, are targeted for destruction. Death of melanocytes leads to the 
appearance of patchy depigmentation on the skin1. Vitiligo affects roughly 1% of the 
population, has no sex bias, and is chronic with the majority of patients developing 
disease before the age of 30. Two major types of vitiligo exist; non-segmental and 
segmental2,3. Non-segmental vitiligo appears in a symmetrical distribution on the body 
and follows an unpredictable disease course. Non-segmental vitiligo often spreads from 
the initial lesion throughout the body and is associated with other autoimmune diseases. 
Segmental vitiligo has a unilateral appearance and is stable with many patients observing 
stability of disease within the first year of vitiligo onset4. Segmental vitiligo is often 
associated with an earlier age of disease onset, and studies report that the prevalence of 
segmental vitiligo is between 5-30% of the total vitiligo population5. Non-segmental 
vitiligo is the most common form of the disease and therefore the work reported in this 
thesis focuses on pathogenesis in non-segmental vitiligo.  
1.2: Psychological burden of vitiligo and associated comorbidities 
	
Vitiligo is a severely disfiguring disease that negatively impacts patients’ quality of life 
and self-esteem 6,7. The psychological burden of vitiligo varies depending on the patients’ 
skin phototype and location of depigmented spots. The history of social stigma associated 
with vitiligo has significantly increased the burden of those living with vitiligo. For 
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example, in Buddhist culture, patients with vitiligo cannot be ordained (Gauthier Y. and 
Benzekri L, 2010), and those of Islamic faith are seen as unfit for marriage and disease 
qualifies them for divorce. In Indian culture, patients with vitiligo as well as their 
children are unsuited to marry. The exclusion and alienation that occurs from these 
principals is devastating for patients. Since vitiligo often affects visible skin, patients 
avoid going out in public and participating in activities such as school or sports in fear of 
being discriminated against8. Vitiligo also brings about anxiety, depression, suicidal 
thoughts, and other psychiatric morbidities to many patients9. Vitiligo has a significant 
impact on patients’ quality of life and the disease burden is comparable to other skin 
inflammatory diseases such as psoriasis and eczema10.  
Patients may develop numerous adverse side effects from vitiligo and its systemic 
associations. Because melanocytes not only exist in the skin, but are also present in the 
eyes, inner ears, and brain, vitiligo patients can develop neurological, ocular and auditory 
abnormalities11. In addition to these co-morbidities, multiple studies show that vitiligo 
patients have increased incidence, up to 25%, of other autoimmune or inflammatory 
diseases including Addison’s disease, type I diabetes, and thyroiditis, amongst others12. A 
major contributing factor is the underlying genetic susceptibility that is shared between 
vitiligo and other autoimmune or inflammatory conditions13.  
1.3: Genetic contributions to vitiligo development 
	
Vitiligo is a complex and multifactorial disease in which stochastic events, genetic 
susceptibility, and environmental triggers play a role. Genetics play a clear part in the 
susceptibility of vitiligo development from early studies that reported an increased 
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frequency of vitiligo in first degree relatives (11-38%) and studies that revealed a vitiligo 
concordance rate of 23% in monozygotic twins 14-16. In addition, vitiligo is 
epidemiologically associated with family members that have vitiligo or other 
autoimmune diseases including Addison’s disease, autoimmune thyroid disease, and type 
I diabetes. The association of vitiligo with multiple autoimmune diseases indicates that 
these autoimmune diseases share at least some genetic risk alleles. In fact early studies 
identified HLA-A2 and HLA-DR4 to be associated with vitiligo, both of which are 
associated with many other autoimmune diseases17,18. Many genes have since been linked 
with vitiligo development through genome wide association studies (GWAS) including 
HLA-A, HLA-DRB1 and HLA-DQA119,20. About half of the identified genetic loci 
encode immune proteins consistent with vitiligo being autoimmune driven. Some of these 
genetic loci include proteins involved in cytotoxicity such as Fas Ligand (FasL) and 
Granzyme B (GZMB), which have predicted functional roles in disease pathogenesis, but 
the biological mechanisms of many others have not yet been identified.  
1.4: Current therapies for vitiligo 
	
Mature melanocytes in healthy human skin are present in both the epidermis and the hair 
follicle to which they provide pigment. The hair follicle also serves as a stem cell 
reservoir and houses epidermal precursor cells including melanocyte stem cells21. In the 
majority of vitiligo patients, only the epidermal melanocytes are targeted for destruction, 
and melanocytes present in the hair follicles remain unaffected. The reasons for this 
remain unclear but mechanisms of immune privilege within the hair follicle may play a 
role22. Because of this, vitiligo can be reversed by both suppressing the immune attack 
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and by stimulating melanocyte precursors that live in the hair follicle to proliferate, 
migrate and replenish lost epidermal melanocytes through a process known as 
perifollicular repigmentation23,24. 
The standard treatment for vitiligo patients is narrow band ultraviolet B (nbUVB) therapy 
in combination with topical corticosteroids or calcineurin inhibitors. Topical 
corticosteroids and calcineurin inhibitors act to broadly suppress the local immune 
response in the skin and nbUVB, which also contributes to immune suppression, 
stimulates melanocyte regeneration from the hair follicles. Current therapy is effective for 
many patients with up to 100% repigmentation possible depending on the anatomical site 
that is affected but is often unpredictable, time consuming, and insufficient for many 
patients25,26. Because hair follicles harbor the melanocyte precursors required for 
repigmentation, anatomical sites devoid of hair follicles, such as the fingertips, knuckles, 
ventral wrists, and elbows, often have poor treatment responses. Also, lesions in which 
the follicular melanocytes have been destroyed, resulting in white hair, often do not 
regain pigment following conventional treatment. Vitiligo is a chronic disease that 
requires lifelong therapy and about 40% of vitiligo patients relapse within 1 year after 
stopping treatment 26 27. Because of the few treatment options, limited access to nbUVB, 
slow and sometimes poor treatment efficacy, and only short-term benefits, there remains 
a significant need to develop targeted and durable treatments.  
1.5: Evidence for innate immunity in vitiligo development   
	
The role of innate immunity in vitiligo development is ill-defined but studies suggest that 
activation of the innate immune system may be involved in initiation of disease. Early 
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evidence suggests that melanocytes from vitiligo patients are intrinsically abnormal 
compared to healthy melanocytes. Melanocytes from vitiligo patients are difficult to 
culture ex vivo and have increased sensitivity to exogenous stress28. Melanocytes from 
vitiligo patients also have dilated endoplasmic reticulum and have increased levels of 
H2O2 and other oxidative by-products, suggesting the presence of increased cellular 
stress29,30. A study defining early gene expression during initiation of disease in a 
spontaneous vitiligo animal model, the Smyth line of chickens, revealed an increase in 
genes involved in melanocyte stress31.  
 
The innate immune system is designed to recognize danger signals, such as cellular stress 
through a variety of mechanisms. Molecular patterns released during sterile inflammation 
are known as damage associated molecular patterns (DAMPs) and are recognized by 
pattern recognition receptors (PRRs)32. For example, the cytosolic nucleotide 
oligomerization domain- like receptor (NLR)-P3 is activated by reactive oxygen species 
and mitochondrial stress33,34. Thus, DAMPs produced or released by melanocytes under 
stress may trigger the innate immune system to initiate inflammation in vitiligo35. 
Infiltration of innate immune cells including macrophages, NK cells, and inflammatory 
dendritic cells have been found in vitiligo skin lesions36,37. However, their role in disease 
pathogenesis requires further investigation.  
 
Another clue into the contribution of innate immune activation in vitiligo is that multiple 
genetic loci encoding innate immune proteins have been identified as GWAS for vitiligo. 
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Both interferon induced with helicase C domain-1 (IFIH1)38, also known as MDA-5, and 
NLRP139, which are intracellular PRRs were identified in GWAS studies to be associated 
with vitiligo40. Activation of these receptors induces production of type I interferons and 
other pro-inflammatory cytokines triggering activation of adaptive immune responses. 
Another gene TICAM1, which encodes the toll like receptor adaptor protein TRIF is also 
associated with vitiligo41. TRIF mediates signaling through TLR3 and TLR4, leading to 
type I interferon production42. The potential activation of PRRs by melanocyte DAMPs 
may not only stimulates activation of innate immune cells but also modulate adaptive 
immune responses through dendritic cell maturation, which promotes T cell activation35. 
Therefore, defining their role in vitiligo development is important.   
1.6: Association of viruses in vitiligo 
	
Development of autoimmunity is multifactorial and environmental insults including 
infection with viruses are associated with triggering autoimmune diseases such as type I 
diabetes, systemic lupus erythematosus (SLE), and multiple sclerosis (MS), but the role 
of viruses in the development of vitiligo is less clear43. Multiple case studies have 
correlated the presence of human immunodeficiency virus (HIV) with vitiligo 
development44,45. Even more interesting, treatment of the chronic virus with antiretroviral 
therapy led to reversal of vitiligo in two patients46,47. Other viruses have also been 
associated with vitiligo including hepatitis C virus (HCV). In HCV patients, the 
development of vitiligo has been reported following treatment with PEGylated interferon 
alpha and retroviral therapy. Some HCV patients developed vitiligo at the injection site 
and others developed disease at distant sites of the body48-50. In addition to these cases, 
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one study presented weak evidence of cytomegalovirus DNA in vitiligo lesional skin51. 
The correlations between chronic virus infection and the development of vitiligo provide 
evidence that virus infections may stimulate pathogenic immune responses against 
melanocytes, but more information is required to conclude their causation of disease.  
1.7: CD8+ T cells are both necessary and sufficient for vitiligo development 
	
It is well established that CD8+ T cells are both necessary and sufficient to mediate 
human vitiligo. Early studies showed that the number of HLA-A2 melanocyte-specific 
CD8+ T cells in the blood of vitiligo patients correlated with disease severity and CD8+ T 
cells expressed high levels of the skin homing receptor, cutaneous lymphocyte-associated 
antigen52. Furthermore, isolated melanocyte-specific CD8+ T cells from vitiligo patients 
were able to lyse HLA-A2 matched peptide pulsed cells and melanoma cells ex vivo 
whereas non-specific CD8+ T cells had no cytolytic ability. Examination of vitiligo 
patient skin cells using suction blistering found that the number of CD8+ T cells is 
significantly increased in active disease compared to stable, non-lesional, and healthy 
control skin53. Furthermore, elegant studies showed that perilesional CD8+ T cells 
isolated from vitiligo skin could kill melanocytes from normal pigmented skin isolated 
from the same patient when cultured ex vivo, demonstrating that melanocyte-specific 
CD8+ T cells are both necessary and sufficient for the destruction of melanocytes54. 
1.8: Transgenic mice used as hosts for mouse model of epidermal depigmentation 
	
In hopes to better understand mechanisms of vitiligo pathogenesis, a mouse model of 
disease was designed. Previous mouse models of vitiligo using C57BL/6 mice led to the 
development of hair depigmentation. This is because C57BL/6 mice have pink skin 
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resulting from the lack of melanocytes within the epidermis. The majority of melanocytes 
in C57BL/6 mice reside in the hair follicles55. Since hair depigmentation is not 
representative of human disease56, Harris et al. developed the first mouse model of 
vitiligo that displayed epidermal depigmentation57.   
Melanocytes require the expression of Kit protein, a receptor tyrosine kinase, for their 
development, migration, and survival. The ligand for Kit, also known as stem cell factor 
(SCF), is produced locally in human skin by multiple cell types including keratinocytes, 
fibroblasts, and endothelial cells58,59. Expression of SCF by epidermal cells directs and 
positions melanocytes within the interfollicular epidermis in human skin. In contrast to 
human skin, the epidermis of adult C57BL/6 mice does not express SCF, and instead 
expression is restricted to the dermis and hair follicles, resulting in melanocytes restricted 
to the hair follicles with only a small number of melanocytes found in the tail and footpad 
epidermis55,60.  
SCF has two forms, a soluble and transmembrane form depending on alternative splicing 
of the protein. Previous studies of SCF identified two proteolytic domains required for 
the generation of soluble SCF and found that mutation of the proteolytic domains 
restricted the protein to the membrane while remaining biologically active61. Transgenic 
mice were generated to express the membrane-bound form of SCF in keratinocytes, 
which make up the majority of cells within the epidermis. To accomplish this, engineered 
mice express SCF driven from the human keratin 14 promoter (KRT14-
kitl*4XTG2Bjl)62. In contrast to wild type C57BL/6 mice that lack SCF expression in the 
epidermis, KRT14-kitl*4XTG2Bjl mice express SCF by epidermal keratinocytes and 
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have black appearing skin owing to the retention of melanocytes in the interfollicular 
epidermal basal layer and follicular epidermis. These host mice are used for all vitiligo 
mouse model experiments in this thesis and are named SCF mice.  
 
 
1.8.1: Melanocyte specific CD8 T cells 
	
Induction of vitiligo in SCF mice requires CD8+ T cell effectors specific for melanocytes.   
Multiple melanocyte-specific proteins recognized during the CD8+ T cell response to 
Figure 1.1:KRT14-kitl*4XTGBjl (SCF) mice. SCF mice have black skin owing to 
melanocyte retention in the epidermis. Images contrast wild-type C57BL/6 and SCF 
transgenic mouse tails, ears, nose and rear footpads (no vitiligo). 
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melanoma had previously been identified. These proteins expressed by melanoma cells 
are also vitiligo autoantigens and are expressed by normal melanocytes63 and are known 
as melanocyte differentiation antigens. One identified protein is premelanosome protein 
(Pmel-1/gp100), which is highly enriched in the melanin-producing organelles of 
melanocytes, called melanosomes. Pmel-1 T cell receptor (TCR) transgenic mice were 
generated by the Restifo laboratory (National Institutes of Health (NIH)), and Pmel-1 T 
cells recognize the melanocyte differentiation antigen gp10025-33 presented on H-2Kb64,65. 
For induction of vitiligo, Pmel-1 TCR transgenic mice are used as the source of effector 
CD8+ T cells and 1 million Pmel-1 are adoptively transferred into SCF recipients by 
retro-orbital injection. Pmel-1 CD8+ T cells are tracked in the SCF recipients by 
expression of the T lymphocyte Thy1a congenic marker or by fluorescent protein 
expression such as green fluorescent protein (GFP). 
 
1.8.2: Infection with vaccinia virus to activate transferred Pmel-1 CD8+ T cells 
	
Activation of transferred naïve Pmel-1 CD8+ T cells recognizing the peptide gp10025-33 is 
required for vitiligo development. The recombinant vaccinia virus used to express gp100 
was generated from the modified vaccinia virus Ankara (MVA). This is an attenuated 
strain of vaccinia virus that was found to have several deletions that reduce its replication 
ability in human and mammalian cells66. Recombinant vaccinia viruses (rVACV) 
encoding mouse gp100 and human gp100 were generated and tested in immunization 
experiments to target melanoma in mice64. Studies showed that only immunization with 
rVACV encoding human gp100 (rVACV-hgp100) induced immune reactivity to both 
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mouse and human gp100 and resulted in a robust CD8+ T response. Recombinant VACV-
hgp100 was a gift from the Restifo laboratory (NIH). Recipient SCF mice are infected the 
same day of Pmel-1 T cell transfer by intraperitoneal (i.p.) injection with rVV-hgp100 to 
induce activation of the transferred Pmel-1 CD8+ T cells in vivo. The infection induces 
the proliferation, expansion, and activation of Pmel-1 CD8+ T cells65.  
1.8.3: Summary of the mouse model 
	
This model of vitiligo is a modification of the adoptive transfer model developed for 
melanoma immunotherapy65. Induction of vitiligo in SCF mice is dependent on sublethal 
irradiation, Pmel-1 CD8+ T cell transfer, and infection with rVACV-hgp100 to activate 
Pmel-1 CD8+ T cells in vivo. The day before Pmel-1 CD8+ T cell transfer, SCF recipient 
mice are sublethally irradiated (500 rad). This step is critical for the synchronization of 
vitiligo and may work by causing lymphocyte cell death to make space for the transferred 
Pmel-1 cells, although the exact role of irradiation in disease initiation is still not clear. 
The following day, 1 million purified Pmel-1 CD8+ T cells are transferred to SCF 
recipient mice by retro-orbital injection. On the same day, SCF recipients are infected 
with 106 pfu rVACV-hgp100 i.p., which causes the activation and expansion of Pmel-1 
CD8+ T cells in vivo65. Induction of vitiligo in SCF mice results in epidermal white spots 
of depigmentation on the tail, ears, footpad, and nose57. The number of infiltrating Pmel-
1 in wild type mice peaks at 5 weeks after vitiligo induction. Infiltration of Pmel-1 to the 
epidermis correlates with depigmentation and melanocyte death. Melanocyte transcripts 
slowly decrease over time and significantly drop by 5 weeks after vitiligo induction57. 
Spots of depigmentation can appear as early as 3 to 4 weeks and continue to develop in 
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severity over time. Wild type SCF mice reach a plateau of vitiligo around 7 to 8 weeks, 
after which the disease stabilizes, and the majority of epidermal Pmel-1 adopt a resident 
memory phenotype defined as CD103+ CD69+ CD44+ CD62L-67.  
 
1.9: IFNγ  and downstream Th1 induced chemokines in disease pathogenesis 
	
Studies using the vitiligo mouse model, as well as studies using vitiligo patient skin, have 
greatly enhanced our understanding of the pathways driving vitiligo pathogenesis as well 
as the signals responsible for the recruitment, positioning, and survival of melanocyte-
specific CD8+ T cells in the skin. Early clinical studies showed that production of the pro-
inflammatory cytokines IFNγ and TNFα  by CD8+ T cells isolated from perilesional 
vitiligo skin positively correlated with disease severity and could predict the success of 
nbUVB therapy68. Likewise, gene expression analysis of vitiligo lesional skin revealed an 
IFNγ-specific gene signature and no upregulation of IL-17 transcripts69,70. These human 
studies point to IFNγ as the central cytokine in disease, and mechanistic studies in mice 






Figure 1.2: Summary of Vitiligo Induction in Mice using vaccinia virus. Host 
SCF mice are sublethally irradiated on Day -1 followed by transfer of Pmel-1 CD8 T 
cells, and infection with recombinant vaccinia virus expressing their cognate 
antigen. SCF mice develop epidermal depigmentation over the course of 7 weeks. 
i.p., intraperitoneal; r.o. retro-orbital.   
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support this hypothesis57,71. The IFNγ signature in mice parallels that seen in human 
patient skin. Affected skin of mice induces a significant increase in IFNγ, and Pmel-1 
CD8+ T cells from vitiligo mice produce IFNγ after stimulation with melanocyte antigen. 
Most importantly, vitiligo progression is dependent on IFNγ as a therapeutic blockade of 
IFNγ significantly reduced the severity of disease57.  
IFNγ stimulates transcription of the chemokine ligands CXCL9, CXCL10, and CXCL11, 
which drive the migration of immune cells into tissues in many type 1 inflammatory 
diseases and infections. All three chemokine ligands bind to the shared receptor, CXCR3, 
which is expressed on activated immune cells, including effector CD4+ T cells, CD8+ T 
cells, and NK cells72,73. Expression of CXCR3 on melanocyte specific CD8+ T cells in 
vitiligo is required for skin tissue homing because CXCR3-deficient CD8+ T cells are 
unable to mediate vitiligo in mice70. This CXCR3-dependent migration is a result of the 
upregulation of CXCL9 and CXCL10 in the skin of vitiligo mice74. In fact, treatment of 
mice with CXCR3 depleting antibodies both prevented and reversed disease75. In vitiligo 
patients, the majority of CD8+ T cells in lesional skin express CXCR367,76,77, and the 
chemokine ligands CXCL9 and CXCL10 are enriched within lesional skin compared 
with non-lesional and healthy control skin70,78. These studies establish the IFNγ-CXCR3-
CXCL9/10 axis as the central pathway in mediating vitiligo and for the recruitment of 
CD8+ T cells into mouse and human skin. 
1.10: The functional roles of CXCL9 and CXCL10 in vitiligo 
	
Mice that report the expression of CXCL9 and CXCL10 were used to determine the 
kinetics and source of CXCR3 ligands in epidermal vitiligo skin79. Global epidermal 
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expression of CXCL9 followed a bimodal pattern; CXCL9 was maximally upregulated 
early after disease induction and then again at the peak of disease74. Epidermal CXCL10 
expression gradually increased over the duration of disease with the highest expression at 
the peak of the immune response in vitiligo74. Induction of vitiligo in CXCL9-deficient 
mice led to a significant reduction of melanocyte specific CD8 T cells in both the 
epidermal and dermal skin compartments, suggesting the importance of CXCL9 for early 
recruitment of CD8 T effector cells to the skin and the development of new lesions70. 
However, CXCL9-deficient mice still developed vitiligo as the few melanocyte-specific 
CD8 T cells that did make it into the skin were evidently sufficient to induce disease70. 
Interestingly, CXCL10-deficient mice and those treated with CXCL10 antibody did not 
show significant defects in bulk recruitment of melanocyte-specific CD8 T effector cells 
into the dermis, but CD8 T cells did not efficiently reach the epidermis, which may be 
partly due to low CD44 expression70. CD44 is important for memory T cell survival, 
activation, and directed migration through the basement membrane80. As a result, 
CXCL10-deficient mice were protected from vitiligo progression. In addition, vitiligo 
could be reversed in mice by treatment with a CXCL10-neutralizing antibody70. These 
results suggest that CXCL10 is critical in both disease progression and maintenance, 
playing an active role in the directed migration and tethering of CD8 memory T cells in 
the epidermis as well as possibly modulating their effector function. A recent study by 
our group used suction blistering of human vitiligo skin to measure IFNγ-induced 
chemokine expression in situ53. We found that active vitiligo patient skin contains 
significantly higher levels of CXCL9 protein than stable skin from vitiligo patients, non-
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lesional skin, and healthy control skin. In fact, the presence of CXCL9 protein in the skin 
is sensitive and specific for disease activity and may serve as a biomarker of early 
treatment responses53. 
1.11: Interferons: an overview 
	
Interferons (IFNs) are a family of cytokines that aid in host defense against pathogens 
and facilitate communication between immune cells. Type I IFNs are evolutionary 
conserved and all vertebrates that have NK, T and B cells, also have one gene encoding 
the type I IFN-β and at least two that encode IFN-α81. Interferons were first discovered in 
1957 to interfere with viral replication82. Interferons are categorized into 3 main classes 
of interferons; type I, type II and type III. In humans, type I IFNs include 13 different 
IFNα genes, 1 IFN-β gene, and several other structurally similar subtypes83. Type II IFN 
is comprised of a single type, IFNγ while type III interferons include 4 different IFN-λ 
subtypes84,85. Each class of IFNs binds to a unique receptor and thus can initiate different 
immune responses.  
Type I IFNs are induced following pathogen infection. Host PRRs are equipped to detect 
a variety of pathogen associated molecular patterns (PAMPs) including bacterial and 
viral DNA and RNA products81. Detection of pathogen components leads to production 
of type I IFNs. Type I IFNs induce a robust anti-viral state through the upregulation of 
hundreds of IFN-stimulated genes (ISGs)86. ISGs function to inhibit all aspects of the 
viral life cycle and although the mechanism of some have been identified the role of 
others remains unknown.  
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1.12: Type I IFNs in host defense 
	
Type I IFNs can be produced by almost all cell types in the body following PRR 
activation. Several types of PRRs have been identified including Toll like receptors 
(TLRs), retinoic acid-inducible gene 1 (RIG-I)-like receptors (RLRs) and nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs) to name a few85,87. These 
receptors detect a variety of different PAMPs on viral, bacterial, and fungal pathogens. 
Here we will focus on those receptors activated by viral components. Two main classes 
of receptors recognize viral pathogens. The first are cytosolic receptors including cGAS-
STING, RIG-I, and MDA5, which are ubiquitously expressed to detect viral nucleic acids 
upon infection. RLRs including both RIG-I and MDA5 recognize RNA products88, 
whereas cGAS recognizes DNA components89. TLRs are the second class of receptors 
that detect viral nucleic acid components. TLRs are located both at the cell membrane 
and in endosomes and have complex expression patterns in different cell types and 
tissues90,91. The subcellular localization of TLRs, and the cell-type specific and temporal 
patterns of TLR expression may result in the activation of different downstream signaling 
pathways and distinct cytokine induced gene expression.  TLRs are activated by different 
ligands. TLR3, detects double stranded-RNA, which is a common feature of both DNA 
and RNA viruses92. Whereas TLR7 and TLR8 recognize viruses with single-stranded 
RNA genomes93-95, and TLR9 recognizes unmethylated CpG motifs which are present in 
DNA viruses96-98. Not only can TLRs directly sense viral nucleic acids, but evidence 
suggests that endosomal TLR3 can detect viral dsRNA coming from apoptotic cells that 
are engulfed99. Since viral infection often leads to apoptosis, indirect detection of viral 
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products from dead cells facilitates cross presentation of viral antigens to CD8 T cells and 
viral control81. This data also suggests that presentation of viral antigens by antigen 
presenting cells (APCs) can occur even from viruses unable to infect APCs, such as 
vaccinia virus. Also, since viruses inhibit host anti-viral responses, presentation of viral 
antigens by uninfected APCs are protected from viral defense mechanisms81.  
Although PRRs use different downstream signaling components, they converge on the 
activation of two main transcription factors; NF-κB and interferon regulatory factor  
(IRF) proteins. The NF-κB  pathway is responsible for the induction of pro-inflammatory 
cytokines, chemokines, and other inflammatory mediators100. Activation of NF-κB occurs 
through transforming growth factor β-activated kinase 1 (TAK1), which then leads to the 
activation of IKK kinase and IκBα phosphorylation100. Downstream activation of NF-κB 
following PRR signaling induces the expression of hundreds of genes that regulate cell 
proliferation, apoptosis, and differentiation. NF-κB activation impacts CD4 T cell 
differentiation through induction of cytokines but also through T cell intrinsic 
mechanisms100-102.  Studies show that following TCR signaling, recruitment of the NF-κB 
family member RelA by T-bet, the master transcriptional regulator of Th1 cells, is 
important for optimal IFNγ production103. T cells deficient in c-Rel show defective Th1 
immune responses and IFNγ production104. NF-κB activation likely impacts CD8 T cell 
differentiation as well100,102.  
 
PRR signaling also leads to the activation of TANK-binding kinase 1 (TBK-1), which 
phosphorylates the transcription factors interferon regulatory factor (IRF) 3/7 to induce 
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transcription of target genes including type I IFN alpha and beta105,106. Endosomal TLRs 
7, 8 and 9 use the adaptor protein myeloid differentiation primary response gene 
(MyD88) to initiate signaling, which can also associate with IRF3/7 independently of 
TBK-1107,108. But endosomal TLR3 and surface TLR4 use the adaptor molecule TIR 
domain containing adaptor inducing IFN-β (TRIF) to activate TBK-1 and phosphorylate 
IRF3/7. The cytosolic RLRs also activate TBK-1 using the mitochondria-associated 
protein mitochondrial anti-viral signaling protein (MAVS)109. Finally, cytosolic DNA 
receptors like cGAS use the adaptor stimulator of IFN genes (STING) to activate IRF3/7 
and type I IFN production110.  
The majority of cells constitutively express IRF3 but only specialized cells express IRF7. 
One of these specialized cell types are known as plasmacytoid DCs (pDCs), which 
constitutively express IRF7 and can produce up to 95% of type I IFNs during systemic 
infections111. Although the role of pDCs in vitiligo is not clear, pDCs have been shown to 
drive autoimmune disease in SLE as well as other auto-inflammatory diseases112-114.  
1.13: Type I IFN signaling pathway 
	
Canonical type I IFN signaling involves the activation of Janus kinase (JAK) and signal 
transducer and activator of transcription (STAT) pathways115,116. Type I IFNs are a 
family of cytokines including IFN-α, β, ε, κ, ϖ, which all bind to the same heterodimeric 
receptor IFNAR1 and IFNAR2117. Upon receptor ligand binding, conformational changes 
leads to auto-phosphorylation and activation of the associated JAK proteins which 
phosphorylate downstream STATs. STAT proteins associate to form hetero- or homo- 
pairs and translocate to the nucleus to induce transcription of genes. JAK-STAT signaling 
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is tightly regulated to prevent immunopathology and the suppressor of cytokine signaling 
(SOCS) family of proteins is one mechanism by which type I IFN signaling is 
regulated118. SOCS proteins modulate JAK-STAT at early stages by direct binding to the 
receptor or to associated kinase proteins119. SOCS proteins can also regulate signaling by 
targeting receptors or JAK proteins for proteosomal degradation.  
IFNAR1/IFNAR2 associate with the Janus kinases JAK1 and TYK2 which phosphorylate 
specific tyrosine residues of signal transducer and activator of transcription (STAT) 
proteins117,120. TYK2 associates with IFNAR1 and JAK1 with IFNAR2. Canonical 
signaling transduction leads to receptor dimerization, and cross-phosphorylation of 
associated kinases. The phosphorylation and activation of Janus kinases allows for STAT 
proteins to dock followed by kinase mediated phosphorylation of STAT1/STAT2 
heterodimers. STAT1/2 form a complex with the transcription factor IRF9 known as the 
IFN-stimulated gene factor 3 (ISGF3) transcription factor complex. ISGF3 translocates to 
the nucleus and binds to IFN-stimulated response elements (ISREs) in the promoters of 
IFN-stimulated genes (ISGs).  
Type I IFNs can induce activation of a variety of STAT proteins including STAT1, 
STAT3, STAT4, STAT5, and STAT6 homodimers. They also stimulate formation of 
STAT1-2, STAT1-3, STAT1-4, STAT1-5, STAT2-3, and STAT5-6 heterodimers and 
activation of different STAT complexes is cell type and context dependent115,121,122. Many 
of these STAT complexes do not bind to ISRE elements in the genome to activate 
transcription but instead bind to IFNγ-activated site (GAS) elements. Some ISGs have 
both ISRE and GAS elements in their promoters but others contain only ISRE or GAS 
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elements123,124. Therefore, the transcription of specific genes and the immune responses 
generated by type I IFN receptor signaling is dependent on the downstream activation of 
certain STAT proteins. Also, IFNα and IFNβ have different binding affinities and 
therefore can induce different antiviral, and immunomodulary responses125-127. For 
instance, interferon beta has a 50 fold higher receptor binding affinity to IFNAR1 than 
interferon alpha 128.  
Type I interferon signaling leads to induction of hundreds of interferon stimulated genes 
(ISGs) that work to coordinate and complexly regulate the anti-viral immune 
response81,86. ISGs inhibit all stages of the viral life cycle but also modulate innate and 
adaptive immune response. In addition to ISG induction, the mitogen-activated protein 
kinase (MAPK) pathway, phosphoinositide 3-kinase (PI3K) pathway, and mammalian 
target of rapamycin (mTOR) pathway are activated downstream of type I IFN signaling83. 
These pathways regulate cell survival, apoptosis, pro-inflammatory cytokine production, 
and metabolism.  
1.14: Function of ISGs in viral host defense 
	
Viral detection by PRRs and downstream type I IFN and ISG induction leads to the 
transcription of many genes that function to inhibit all stages of the viral life cycle 
including viral attachment, fusion, replication, transcription, translation, and release81. 
For example, the interferon stimulated gene 2’-5’ oligoadenylate synthases (OAS) 
function to activate the nuclease RNase L, resulting in degradation of viral RNA 
transcripts 121. Degradation of viral RNA inhibits viral replication and can promote 
sensing of viral products by PRRs to enhance the anti-viral state129,130. Another induced 
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ISG is protein kinase R (PKR). PKR is part of the eukaryotic initiation factor 2α (eIF2α) 
kinase family. PKR activation leads to phosphorylation of eIF2α, which blocks 
translation of cellular and viral mRNAs129,131. Because many viruses require host 
machinery to complete their life cycle, blocking host mRNAs is equally important. Some 
ISGs function more specifically. For example, APOBEC3 targets retroviruses such as 
HIV by inhibiting reverse transcription through induction of mutations132. Another class 
of induced ISGs are the Myxoma GTPases known as MX family proteins. These 
GTPases differ in their ability to restrict virus infection and have specific protective 
effects against VSV and influenza133,134.  
1.15: Type I Interferon Signaling on Effector Cells  
	
Type I IFNs can modulate the immune system in a cell type, time, and context dependent 
manner135. Type I IFNs mediate their effects either directly, through IFNAR signaling or 
indirectly through the induction of other pro-inflammatory cytokines or chemokines. Two 
effector cell populations that are responsible for killing of infected cells, NK cells and 
CD8 T cells, are directly and indirectly affected by type I IFNs.  
Type I IFNs have direct effects on NK cell survival and cytotoxicity136. Direct type I IFN 
signaling increases NK cell cytotoxic function by inducing cytotoxic effector molecules 
like perforin and granzymes136. Type I IFNs also promote NK cell survival indirectly 
through STAT1-dependent induction of IL-15137.  
Type I IFNs contribute indirectly to the activation of effector cell populations like CD8 T 
cells through maturation of DCs, which can aid in cross presentation of naïve T cells 138. 
Similarly, type I IFN signaling has a direct co-stimulatory effect on CD8 T cell 
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proliferation, differentiation and expansion139-141. One study showed that type I IFN 
provides a third signal to CD8 T cells during antigen recognition via STAT4-activation 
that stimulates survival, development and cytolytic function including IFNγ139. However, 
type I IFN was shown to limit non-specific T cell expansion in a STAT1 dependent 
manner142, highlighting the differential effects of type I IFNs. Timing of type I IFN 
signaling can also affect the magnitude of the CD8 T cell response. CD8 T cells exposed 
to type I IFNs before or during the time of antigen exposure induced significant effector 
function capabilities including production of IFNγ143,144. However, sustained type I IFN 
can have immunosuppressive effects on CD8 T cells by inducing T cell exhaustion145,146. 
Direct cellular type I IFN signaling is critical for the anti-viral CD8 T cell response to 
lymphocyte choriomeningitis virus (LCMV). Direct type I IFN was not required for 
proliferation but was required for the survival of CD8 T cells during the priming phase of 
LCMV infection and for memory formation140. In contrast to LCMV, CD8 T cell 
responses to vaccinia virus infection do not require direct type I IFN signaling, but 
instead require IL-12, which can also provide co-stimulatory signals to T cells during 
activation147,148. Furthermore, low dose vaccination with modified vaccinia virus did not 
require type I IFN signaling for cellular immunity as CD8 T cell responses to MVA 
vaccination were similar between wild type and IFNAR deficient mice149. These results 
highlight the context-specific role of type I IFN on effector CD8 T cells, and these studies 
provide evidence of two types of CD8 T cells; those that require type I IFNs for 
expansion and function and those that do not. Type I IFNs also indirectly affect CD8 T 
cells. For example, studies show that IL-15 enhances CD8 T cell proliferation and 
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effector memory formation in vivo150, and we have shown its importance in vitiligo for 
resident memory T cell survival67.  
Type I IFNs also modulate T cell responses through their actions on dendritic cells 
(DCs). Type I IFNs are important for the activation of immature DCs. Type I IFN 
signaling directly induces expression of MHC class I and II and the costimulatory 
molecules CD80 and CD86151,152, which supports naïve T cell activation. Presentation of 
class I peptides are derived from antigens in the host cells cytosol, while class II peptides 
are derived from extracellular proteins or from self-proteins that are degraded in the 
endosomal pathway153. Certain APCs, including CD8α+ DCs, can take up and process 
extracellular antigens and present peptides on MHC Class I to CD8 T cells in a process 
known as cross-presentation154. Type I IFNs signaling on DCs has been shown to 
enhance cross-presentation to CD8 T cells155,156. Because activation of CD8 T cells 
licenses them to kill infected cells or tumor cells, cross-presentation is critical for 
immunity against tumors and viruses. Type I IFNs were also shown to induce IL-12 
production by DCs and IL-12 has potent co-stimulatory effects on CD8 T cells during 
priming157. Type I IFNs can also enhance T cell activation by increasing migration of 
DCs to the lymph nodes through the upregulation of chemokines receptors like 
CCR7158,159. Thus the direct and indirect effects of type I IFNs on effector cells act to 
enhance anti-viral immunity.   
1.16: Type I interferons in autoimmunity 
	
Type I IFNs can have both beneficial and deleterious effects on human autoimmune 
diseases. For example, type I IFNs drive pathogenesis in systemic lupus erythematosus 
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(SLE)160, but have protective effects for the autoimmune disease multiple sclerosis 
(MS)161. SLE is a complex and multifactorial disease but about 87% of patients have a 
type I IFN gene signature and type I IFNs are able to predict disease outcomes162 and are 
used as biomarkers. One of the primary sources of IFN production in SLE is by pDCs. 
Increased type I IFNs may result from the accumulation of extracellular and intracellular 
self-nucleic acids through increased cell damage/apoptosis or defects in cell 
clearance163,164. Dysregulated PRR activation driving type I IFN production in SLE has 
also been implicated in disease. Using a mouse model of SLE, TLR9 signaling was 
shown to suppress immune activation in the skin because TLR9 deficient mice developed 
more clinical manifestations of SLE, and this was dependent on the presence of TLR7165. 
Another disease mediated by dysregulated type I FIN production is Sjogrens 
syndrome166. Sjogrens syndrome is an autoimmune disease that affects the exocrine 
glands and patients with an interferon gene signature have increased B cell activating 
factor (BAFF) expression and increased autoantibodies167,168. Interestingly, a phase 2 
study on the use of an anti-BAFF antibody for patients with Sjogrens syndrome found 
that two subpopulations of patients may exist; one with a type I IFN signature and one 
with a type II IFN signature169. Type I IFN receptor signaling was also shown to induce 
pathogenic responses to self in a rat model of virus induced diabetes170. In contrast, 
IFNβ-1a has clinical efficacy for the treatment of relapsing remitting multiple sclerosis 
(RRMS)171. The mechanism of action is not fully understood, but studies show that the 
induction of IL-10, an anti-inflammatory cytokine, blockade of T cell migration through 
reduced metalloprotease and adhesion molecule expression, and induction of Tregs may 
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play a role in its efficacy172,173. Thus, type I IFNs can promote pathogenic or protective 
responses in autoimmunity and its mechanism of action is complex, owing to the 
heterogeneous immune responses involved in autoimmune development and the 
pleiotropic effects of type I IFNs.  
1.17: Type I and type II interferon signaling overlap and antagonism   
  
Type I and type II interferon, IFNγ, bind to different cell surface receptors, but can 
induce transcription of multiple overlapping gene targets and thus promote similar 
immune programs. This is because the activation of STAT1 homodimers occurs 
downstream of both type I and type II IFN signaling117,174. Type I IFNs can induce 
CXCL9 and CXCL10 to attract and stimulate effector CD8 T cells175. Type I IFN 
induction of pro-inflammatory cytokines including CXCL9 and CXCL10 through STAT1 
homodimer activation is regulated in part by STAT3176. STAT3 antagonizes STAT1 by 
competing for STAT1 association and through DNA binding. Thus the contribution of 
type I IFN in inducing CXCL9 and CXCL10 may be part due to the expression of cellular 
STAT3. Studies reveal that both type I and type II interferon can act synergistically177. 
Type I IFN signaling induces STAT1 expression, which can prime cells to respond to 
cytokines that use STAT1 for downstream signaling including IFNγ178. As discussed 
earlier, because some ISGs contain both ISRE and GAS elements in their promoters, they 
can be induced by both type I and type II interferon. IFITM1, an anti-viral protein that 
prevents viral entry into host cells, is one example of a gene regulated by both type I and 
type II IFN. 179 
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Type I and type II interferon can also induce opposing effects and a good example of this 
is following microbial infections180,181. Mycobacterium leprae induces two different 
clinical presentations; one in which few skin lesions develop resulting from low bacterial 
count and the second in which bacteria become disseminated and the host immune 
response fails. Gene expression data revealed an inverse correlation between IFN-β and 
IFNγ. The authors reveal that IFN-β induced IL-10 led to disseminated disease through 
inhibition of the antimicrobial pathways induced by IFNγ181. Thus defining the biological 
function of type I IFN in vitiligo and its potential regulation of IFNγ responses is critical 
for our understanding of disease pathogenesis.  
1.18: Vaccinia Virus 
	
Vaccinia virus (VACV) is a member of the highly conserved Poxviridae family and is 
one of the most extensively studied viruses because VACV served as the vaccine that 
eradicated smallpox, the human disease produced by the Poxviridae variola virus182. In 
vitro studies have revealed that VACV has broad cellular tropism183. Despite this, a 
specific host receptor for VACV entry has not been identified. Vaccinia virus is a large 
(130,000 – 375,0000 nts) linear double stranded DNA virus that replicates in the 
cytoplasm. Specifically, studies report that VACV DNA synthesis occurs within the 
endoplasmic reticulum in enclosed mini-nuclei 184,185. Because VACV does not require 
the host cell nucleus, VACV is capable of replicating in differentiated keratinocytes, cells 
that have shed their nuclei. However, infection of human skin with vaccinia virus 
revealed productive infection in dermal fibroblasts and dermal endothelial cells but 
reduced infection in keratinocytes186. Only early VACV gene products were detected in 
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epidermal Langerhans cells, dermal dendritic cells, and skin T cells, suggesting that these 
cell types either have mechanisms to suppress viral infection or have reduced 
permissibility of vaccinia virus entry186. Interestingly, infection of keratinocytes with 
VACV led to production of immune suppressive cytokines including IL-10 and TGF-
beta186. The authors propose this may be an invasion strategy of VACV that also impacts 
CD8 T cell responses. Differences in cellular or tissue permissiveness to VACV may 
result from the disparate expression of host factors required for VACV life cycle or 
differences in expression of restriction factors such as viral RNA and DNA sensors and 
their signaling pathways that limit viral replication.  
1.19: Cellular Immunity to Vaccinia Virus 
	
Studies investigating the protective immune responses against VACV indicate a role for 
both the innate and adaptive immune system. Infection of mice with Western Reserve 
strain of VACV showed that both antibody production, and CD4 and CD8 T cell 
responses play a role in protection187. Mice deficient in either B or CD4 T cells had 
significantly higher VACV titers compared to wild type mice, and the authors further 
reveal the importance of CD4 T cells in mounting a humoral response to VACV. Mice 
lacking CD8 T cells did not show any differences in VACV titers187. However, infection 
induced robust IFNγ production by CD8 T cells and these cells are required for protection 
against VACV rechallenge. Other studies reveal an important role of Th1 cytokines, 
including TNFα, IFNγ, and type I IFNs in controlling vaccinia virus infection188,189. 
Natural killer (NK) cells also play an important role in both the detection of vaccinia 
virus infected cells and in controlling vaccinia virus replication190,191. Studies reveal that 
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type I IFN production following VACV infection is required for NK cell activation and 
for early control of vaccinia virus since type I IFN receptor deficient NK cells were 
unable to control VACV replication or induce lysis of target cells191. 
1.20: Detection of vaccinia virus by the host 
	
VACV is a double stranded DNA virus, thus VACV is likely to trigger cellular PRRs that 
sense DNA192. Cyclic GMP-AMP synthase (cGAS) is a nucleotidyltransferase that 
generates cyclic GMP-AMP (cGAMP) upon binding to dsDNA in the cytosol193. cGAMP 
acts as a secondary messenger that binds to stimulator of interferon genes (STING) to 
induce activation of IRFs and NF-κB89,194,195. STING is an endoplasmic reticulum-
associated protein that induces type I IFN production in response to viral, tumor, or self 
DNA. Early studies reported the importance of STING for inducing CD8 T cell responses 
against vaccinia virus infection194. Further studies revealed that cGAS-STING was 
required for the detection of vaccinia virus in mouse cDCs and for downstream activation 
of IRF3 and type I IFN production196. Interestingly, infection of vaccinia virus in murine 
cDCs but not pDCs led to type I IFN production 196. Type I IFN production was 
dependent on IRF3/7/and type I IFN receptor signaling. The authors also report a minor 
role for TLR9, which detects DNA containing CpG motifs, and MyD88 in host vaccinia 
virus sensing. Absent in melanoma 2 (Aim2), a cytosolic sensor that directly binds DNA, 
may also detect VACV197. Studies revealed that vaccinia virus infection in Aim2 
deficient dendritic cells showed a complete abrogation of IFNβ compared to infection in 
WT DCs, suggesting that Aim2 may also be involved in the sensing of vaccinia virus197.  
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In addition to type I IFNs, studies reveal that vaccinia virus infection led to induction of 
the pro-inflammatory cytokines TNFα, IL-6, IL-1β, and IL-12 and these cytokines and 
chemokines were also induced following infection of human macrophages with vaccinia 
virus 198. Expression of the chemokine MIP-2 by vaccinia virus infection was dependent 
on TLR2, TLR6, and MyD88. Using shRNA targeted knock down of cytosolic PRRs, the 
authors suggest that IFIH1 (MDA5) is important for inducing IFNβ in response to 
vaccinia virus infection in macrophages198. Collectively, these studies suggest that 
vaccinia virus detection and downstream innate immune signaling activation may vary 
depending on the host cell type or tissue and expression of certain PRRs or viral 
intermediates.  
1.21: Vaccinia virus defense mechanisms 
	
Many viruses have adapted ways to inhibit host cell detection and downstream type I IFN 
production. In fact, viruses can inhibit almost every part of the type I IFN pathway 
including production of secreted decoy receptors, chemokines or cytokines, directly 
inhibiting signaling components, as well as inhibition of specific ISGs199. Vaccinia virus 
is no exception and about 20 genes have been identified that interfere with intracellular 
interferon signaling, chemokine production, and cytokine production200. Vaccinia virus 
encodes a few proteins that inhibit the broad effects of host anti-viral defense. E3/E3L 
can inhibit PKR activity by directly binding to PKR and preventing PKR-induced 
apoptosis201. E3 can also bind to dsRNA and prevent activation of 2’-5’ OAS-
RNaseL202,203. Vaccinia virus can also block the functions of eIF2α through 2 additional 
proteins K3 and C7204. K3 is a homolog of eIF2α and inhibits PKR and prevents eIF2α 
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phosphorylation205. In addition, VACV can evade detection by the immune system by 
targeting PRRs and components of downstream signaling. The vaccinia virus protein A46 
can directly bind to all four TLR4 adaptors MyD88, MAL, TRIF, and TRAM and inhibit 
the downstream activation of  NF-κB, IRF and MAPK pathways induced by TLR 
signaling206,207, suggesting the importance of these signaling pathways in VACV host 
defense206,208. For instance, studies reveal that TRIF mediated activation of IRF3 and 
induction of IFN by TLR3 or TLR4 suppressed VACV replication in macrophages206. 
Likewise, another early expressed VACV protein A52 can interfere with downstream 
TLR molecules TRAF6 and IRAK-2, and can enhance IL-10 production through TRAF6 
to induce immunosuppression209. Protein K7/K7R inhibits IFNβ through inhibition of 
TBK1/IKK-ε mediated IRF3 activation, because K7 can bind to DDX3210. NL1 has a 
similar function to K7 and can block NF-κB and IRF3 activation by direct binding of the 
inhibitor IKK complex and TBK1. In addition to N1/N1L, VACV also encodes several 
NF-κB inhibitors which may be more potent than N1 in suppressing NF-κB signaling211. 
Vaccinia virus can also and interfere directly with type I IFN signaling with encoded 
protein B19/B19R, which acts as a decoy and is a secreted type I IFN receptor that binds 
to type I IFNs thus preventing binding to the host type I IFN receptor212. VACV also 
encodes a soluble IFNγ receptor, B8/B8R, to inhibit host IFNγ signaling213,214 and can 
inhibit the activity of CC chemokines through the protein C23/C23L which binds to CC 
chemokines215. Because vaccinia virus encodes specialized proteins to inhibit type I IFN 
signaling, infection with wild type strains does not induce strong type I IFN 
production216.    
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1.22: Attenuated vaccinia virus strain vs wild type strains 
	
Recombinant vaccinia virus expressing gp100 was generated from an attenuated non-
replicating poxvirus variant217-219. Modified vaccinia Ankara (MVA) is a replication-
defective virus strain derived by passaging more than 570 times in chicken embryo 
fibroblasts220. It has been used to vaccinate in Germany and presented with no adverse 
side effects but its effectiveness against smallpox remains unknown. Sequencing studies 
revealed that MVA has several large deletions, about 30kb, in its terminal regions and 
contains numerous point mutations relative to the replication-competent VACV strains 
221. Many of the deletions/mutations are in viral defense genes, preventing the virus from 
overcoming the host anti-viral state. MVA lacks a few immunomodulatory genes 
encoding soluble receptors for type I IFNs, TNF and CC chemokines222, and only has one 
copy of the E3L gene responsible for PKR inhibition. MVA makes early, intermediate, 
and late proteins but only immature virions223. One major difference between parental 
strains and MVA is that unlike wild type vaccinia strains, MVA can infect and causes 
enhanced activation of human dendritic cells224,225. It is speculated that this is one of the 
reasons for its high immunogenicity. Since MVA lacks multiple genes required for 
inhibition of type I IFNs, infection with this attenuated strain induces type I IFN 
production while infection with the wild-type vaccinia strain fails to induce type I IFNs, 
and results in attenuated innate immune responses to TLR ligands LSP and poly IC226.  
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DNA viruses require the conversion of ribonucleotides to deoxynucleotides for DNA 
replication. Ribonucleotide reductase (RR) is the key enzyme responsible for this process 
and catalyzes the reduction of rNDPs to dNDPs227. RR enzymes are composed of large 
and small protein subunits227. Mammalian cells encode a single large subunit gene and 2 
small subunit genes. Orthopoxviruses including VACV encode both a large and small 
ribonucleotide reductase subunit protein228 identified to be I4L and F4L229-231. Studies 
have shown that inactivating the VACV large subunit I4L did not affect DNA replication 
or viral particle production when compared to the wild type strain and was only mildly 
attenuated232,233. In contrast, inactivation of the small subunit F4L led to significant 
attenuation of VACV234. However, these studies were performed independently and used 
different VACV strains. A comparison study was conducted that generated both large and 
small RR subunit VACV mutant strains235. In this study the authors report that the small 
RR subunit is more critical for VACV replication. Small subunit VACV mutant strains 
exhibited plaque forming defects, impaired replication kinetics in vitro, and impaired 
DNA synthesis compared with I4L mutants235. The authors also reveal that the small 
VACV RR subunit F4L forms an active complex with host large RR subunit proteins to 
ensure viral replication235. Infection of mice with VACV mutants revealed that the small 
subunit F4L mutant was highly attenuated as shown by significantly reduced viral titters 
on day 5 post infection235.  
 
Recombinant vaccinia virus expressing gp100 was generated by insertion of the human 
gp100 minigene through homologous recombination into the VACV locus encoding the 
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small subunit of viral ribonucleotide reductase (RR)64. Minigenes were constructed using 
a recombination plasmid pKT140164. pKT1401 was then recombined into the VACV RR 
locus64. Since, human gp100 was inserted into the small RR subunit, this VACV strain 
was expected to be highly attenuated based on previous studies235.  
We tested whether the recombinant VACV expressing gp100 induced type I IFN 
production following infection in mice. To test this, we used an IFNβ reporter mouse that 
expresses enhanced yellow fluorescent protein (EYFP). The reporter mouse was 
generated using an EYFP targeting vector in which a knockin of EYFP was inserted into 
the endogenous ifnb locus immediately following the STOP codon of the ifnb open 
reading frame. IFNβ reporter expression was validated using different IFN inducing 
agents and visualization of EYFP by flow cytometry and immunofluorescence. We 
induced vitiligo in mice using the protocol described in 1.8 and then examined IFNβ 
reporter expression in the spleen of mice following VACV infection. Our results show 
that the percentage of IFNβ-EYFP expressing cells increases over the course of infection 
in WT hosts. At day 3 post infection about 10% of CD45 positive splenocytes express 
EYFP, while at days 7 and 10 post infection an average of 40% of CD45 positive 
splenocytes express EYFP. This data is preliminary, but suggests that infection with 





Type I IFNs are critical anti-viral proteins and VACV host immunity requires both type I 
IFN and IFNγ for effective clearance. Our IFNβ data suggests that type I IFN production 
induced following infection with recombinant gp100 expressing VACV is important for 
host anti-viral immunity. Interestingly, IFNβ reporter expression peaked at 7 days post 
infection and was sustained at 10 days post infection. Thus, the attenuation of VACV 
through insertion of gp100 into the small subunit RR gene may delay and attenuate its 
replication, but also enhances the susceptibility of this virus strain to type I IFN mediated 














































Figure 1.3: IFNβ-EYFP reporter expression increases following infection with VACV in mice. 
A) EYFP reporter expression following infection with VACV or uninfected controls at days 3, 5, 
7, and 10 post infection. B) Quantification of the percentage of CD45 positive EYFP-IFNβ 




1.23: Melanoma and vitiligo: an overview 
	
Melanoma is an aggressive skin cancer that arises from mutations in melanocytes and has 
a high mortality rate and mean survival of only 6-11 months236,237. It is now well 
established that the innate and adaptive immune system play an integral part in the 
surveillance, recognition, and persistence of tumors including melanoma238,239. CD8 T 
cells recognizing tumor-specific antigens are critical for the anti-tumor response, and 
have been the target of immunotherapies for melanoma240,241. The association between 
vitiligo and melanoma has been long recognized after many case studies reported the 
development of vitiligo following treatment of melanoma242,243. Research in tumor 
immunology has revealed a strong correlation between tumor immunity and 
autoimmunity and this is because of the overlap of antigens expressed by both normal 
and malignant cells63,244. Early in vitro studies of melanoma cell lines and melanocytes 
from normal skin led to the identification of a class of antigens expressed by both. 
Antigens expressed by both melanoma cells and normal human melanocytes are 
classified as melanocyte differentiation antigens (MDAs) 63,245. Some of these identified 
antigens include the melanocyte proteins tyrosinase and tyrosinase related proteins (TRP-
1 and TRP-2), as well as premelanosome protein (Pmel-1/gp100) and MART1/Melan-A, 
all which play roles in melanin synthesis. The association between vitiligo and melanoma 
is well established following early case reports in which patients developed vitiligo after 
melanoma immunotherapy242,243,246. Many studies have followed and it is accepted that 
vitiligo is an independent positive prognostic factor for melanoma patients247. Patients 
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receiving melanoma immunotherapy have increased incidence of vitiligo 248 249,250. 
Similarly, melanoma patients that developed vitiligo following treatment with anti-PD-1 
(pembrolizumab) or anti-CTLA4 (ipilimumab) immunotherapies have increased overall 
survival compared to those who did not develop vitiligo251. It is not completely 
understood why the development of vitiligo is a positive prognostic factor but many 
hypothesize it is due to enhanced CD8 T cell responses against malignant melanoma that 
leads to enhanced CD8 T cell responses against epidermal melanocytes. Genetic studies 
also indicate an inverse relationship between vitiligo and cancer risk, suggesting that 
enhanced immune activation in vitiligo protects against melanoma252.  
In addition to these clinical findings, studies in mice have also modeled this relationship 
to better understand the mechanisms behind the association. Studies by the Turk lab 
reveal that following dermal B16 inoculation, depletion of Tregs, and resection of the 
tumor can lead to vitiligo development evident by hair depigmentation253. In this model 
the authors show increased resident memory CD8 T cell formation in the skin of mice 
that developed vitiligo compared to those that did not. They further reveal that resident 
memory CD8 T cells were required for protection against melanoma re-challenge253. 
Another report also describes the role of resident memory CD8 T cells in mediating 
immunosurveillance of nascent tumors and protection against melanoma254. Collectively, 
these studies suggest that melanocyte/melanoma specific CD8 T cell memory formation 
that occurs following vitiligo development provides protection against tumor 
development through continued skin immunosurveillance and suggests that CD8 T cells 
are a major contributor to the link between vitiligo and melanoma.  
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1.24: Type I IFNs and melanoma  
	
It is well established that type I IFNs have significant effects in promoting tumor 
immunogenicity through dendritic cell maturation, survival and cross-presentation of 
tumor antigens to T cells138,255. Studies report that the activation of cGAS-STING by 
tumor derived DNA in DCs is required for induction of type I IFNs and activation of the 
anti-tumor response leading to tumor regression256. A recent study revealed that infection 
of cDCs with heat or UV inactivated MVA led to significantly higher type I IFN levels 
than MVA alone and this was mediated through the STING pathway257. Intra-tumoral 
injection of inactivated MVA led to induction of antitumor immunity against melanoma 
in mice257. The authors also show that the use of local MVA vaccination along with 
systemic immune checkpoint blockade generated synergistic antitumor effects257. Other 
studies have revealed that IFNaR deficient mice have defective tumor induced T cell 
priming, and that type I IFN signaling on DCs is critical for tumor rejection, and for 
accumulation in the tumor258,259.  
 
The efficacy of type I IFNs in the treatment of melanoma is controversial. Early studies 
supported a role for type I IFN in stimulating the anti-tumor response to melanoma. 
These studies showed that induction of cell death following radiotherapy led to release of 
tumor associated nucleic acids, activation of innate immune PRRs and production of type 
I IFNs. Production of type I IFNs by myeloid cells following radiotherapy were shown to 
be critical for tumor regression and type I IFNs induced CXCR3 mediated migration of  
CD8 T cells into the tumor260,261. Because of these initial findings, IFN therapy was 
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hypothesized to have great success in the clinic. High dose IFN-α-2b therapy was 
approved for treatment of stage IIB/III melanoma262. IFN-α induced MHC Class I on 
immune cells and induced apoptosis of melanoma cells263. Although initial studies found 
that adjuvant IFN-α improved the overall survival of patients, it became clear that only a 
subset of patients respond to IFN therapy264,265.  Pegylated IFN, IFN- α-2b combined 
with polyethylene glycol, was designed to increase the half-life of IFN-α and improve 
adjuvant therapy266. PEG-IFN was approved for adjuvant therapy for stage III melanoma 
in 2011267,268.  The immunomodulary effects of IFN adjuvant therapies were shown to 
enhance innate immune recognition of tumor derived nucleic acids, migration of CD8α+ 
DCs into the tumor, and thus had potent effects on T cell-mediated cytotoxicity269-271. 
However, one clinical study reported significant improvements in relapse-free survival, 
but no difference in overall survival. The other study reported no significant 
improvement following IFN-α adjuvant therapy and treatment was associated with high 
toxicity.  
 
Despite the robust immunostimulatory properties of type I IFNs on DCs and CD8 T cells 
on the anti-tumor response, its use in the clinic did not prove to be as successful. This 
may be a result of type I IFN mediated resistance. One mechanism of resistance is 
downregulation of the type I IFN receptor, IFNaR. Studies in a mouse model of 
melanoma revealed that IFNaR signaling is critical for the suppression of melanoma 
progression272. Using a IFNAR1 mutant that is resistant to downregulation, the authors 
reveal delayed melanoma development, reduced metastatic disease and improved 
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responses to immunotherapies like anti-PD-1. Another mechanism of IFN resistance is 
modulation of signaling downstream of IFNaR. One study revealed an upregulation of 
STAT5 in IFN resistant melanoma cells that led to the suppression of STAT1 activation 
through the upregulation of the cytokine inhibitor CIS273. Melanoma tumors have also 
become resistant to immune-checkpoint inhibitors such as anti-PD-1 by modulation of 
JAKs274. Sequencing studies of two patients’ resistant to pembrolizumab revealed a loss 
of function mutations in JAK1 and JAK2. The presence of JAK1 mutations led to 
resistance to IFNγ, IFN-α, and IFN-β, whereas JAK2 mutations only abrogated IFNγ 
responsiveness274.  
Another explanation for the failure of type I IFN adjuvant therapy in the clinic is that type 
I IFNs can contribute to an immunosuppressive tumor microenvironment. Since type I 
IFNs can induce PD-1 on T cells, PD-L1 on tumor cells 275, IL-10, and the expression of 
indoleamine 2,3-dioxygenase (IDO) it remains likely that sustained or chronic IFN in the 
tumor microenvironment may lead to suppression of the anti-tumor response and 
resistance to immune checkpoint immunotherapies145,276-278. However, a better 
understanding of the role of type I IFNs on the tumor microenvironment and the 
development of combination therapies to overcome resistance mechanisms to IFN will 
improve the treatment of melanoma.  
1.25: Vaccinia virus as a cancer vaccine 
	
Vaccinia virus (VACV) is part of the family of viruses known as Poxviridae, genus 
Orthopoxvirus. Because of its highly conserved nature, immunization with VACV 
provides cross-protection against all other orthopoxviruses such as variola and 
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monkeypox279. VACV is a double stranded DNA virus with a large genome (~180Kb) 
and 200 genes, which allows for the insertion and high level expression of large foreign 
genes, making them ideal for recombinant vaccine vectors 279. VACV can efficiently 
express large transgenes or express multiple transgenes up to 40 Kb280,281. Another 
advantage of VACV as a vaccine is that it replicates completely in the cytoplasm and 
poses no risk of integration of inserted DNA into the genome. Because VACV has 
proven to be efficacious and safe, it is an attractive vector for cancer immunotherapies282.   
VACV has been explored for the treatment of multiple cancer types but I will focus on 
VACV vaccines for melanoma immunotherapy. One of the first uses of vaccinia virus in 
cancer was for metastatic melanoma in which the Wyeth strain of vaccinia virus was used 
by direct injection into the tumor283. Results showed an objective response rate of 50% 
with only mild side effects resulting from the live virus infection. An early clinical study 
revealed that injection of a replication restrictive VACV strain expressing IL-2 in patients 
with mesothelioma was well tolerated and persisted even in the presence of VACV 
antibodies284. VACV has been extensively used to express tumor-associated antigens in 
hopes of activating specific cytotoxic T lymphocyte (CTL) responses in preclinical 
studies. Modified vaccinia virus Anakara engineered to express the melanocyte 
differentiation antigen tyrosinase was shown to induce robust CTL responses285. Other 
studies investigated whether recombinant VACV expression of an ER targeted 
MART1/Melan-A mini gene or expression of the complete MART1/Melan-A protein 
induced better CTL responses286. The authors reveal that the expression of the mini gene 
induced 10-1000 fold stronger responses than expression of the full length protein. In 
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another study, the expression of three melanocyte differentiation antigens, MelanA, 
gp100, and tyrosinase were expressed by recombinant vaccinia virus vaccine and used to 
immunize metastatic melanoma patients287. Vaccination led to increased frequencies of 
cytotoxic T cells specific for these antigens and was associated with improved clinical 
responses.   
Another vaccination strategy has been to infect DCs to activate CTL responses against 
certain tumor associated antigens. Not only can vaccinia vector expressing DCs present 
melanocyte differentiation antigens to CTLs directly but apoptotic DCs can be 
phagocytosed by nearby DCs resulting in amplification of the CTL response. A few 
studies used this approach by infecting mature human dendritic cells with recombinant 
VACV expressing melanocyte differentiation antigens such as gp100 to induce CD8 T 
cell responses against tumor cells288,289. These studies showed induction of strong T cell 
responses against melanocyte differentiation antigens. A clinical trial also used 
autologous CD34 positive DCs transduced with recombinant vaccinia virus expressing 
tyrosinase290.  
Two early clinical trials used recombinant fowlpox, also a Poxviridae family member, 
and recombinant vaccinia virus for the treatment of metastatic melanoma and revealed 
increased frequencies of CTL responses in some patients and the treatment was well 
tolerated 291,292. Another clinical trial used a non-replicative vaccinia virus expressing 
multiple melanocyte differentiation antigens (MART-1, gp100 and tyrosinase) as well as 
the co-stimulatory molecules CD80 and CD86 for use in metastatic melanoma293. Their 
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study showed that 15 out of 18 patients had significant CTL responses against these 
antigens with 3 patients showing tumor regression.  
More recently, the use of a Herpes Simplex Virus (HSV)-1 based talimogene 
laherparepvec (TVEC) has been approved for the treatment of metastatic melanoma294. 
TVEC is a genetically modified HSV-1 that preferentially replicates in tumor cells. Lysis 
of tumor cells following administration of TVEC can enhance cross presentation of tumor 
antigens and lead to anti-tumor immunity at distant uninjected sites. Cancer cells usually 
downregulate type I IFNs to promote unrestrained proliferation, and this is advantageous 
for oncolytic viruses such as HSV-1 and VACV, which allows for their unrestrained 
replication in cancer cells295. A recent report engineered HSV-1 and VACV to express 
tumor associated antigens on the viral envelope and revealed that this could induce strong 
CTL responses against B16F10 melanomas in mice296. In these studies, VACV 
performed as well or better than HSV-1 at stimulating robust anti-tumor immunity. Thus, 
the use of VACV for immunotherapy for melanoma is safe and the development of 
improved VACV therapies is ongoing. But a better understanding of the signals driving 
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Vitiligo is a disfiguring skin disease in which autoreactive CD8+ T cells target and 
destroy melanocytes, the pigment-producing cells of the epidermis, leading to patchy 
depigmentation52,68. Vitiligo affects roughly 1% of the population worldwide and 
currently there are no FDA approved medical treatments to reverse the disease1,2,297,298. 
Our lab and others have shown that signaling through type II interferon, IFN-gamma 
(IFNγ), is critical for disease pathogenesis in human patients and in a mouse model of 
vitiligo53,54,57,70. Previous work has identified epidermal IFNγ signaling and the induction 
of the chemokine ligands CXCL9 and CXCL10 in promoting migration of anti-
melanocyte CXCR3-expressing CD8+ T cells to the epidermal-dermal junction where 
they mediate elimination of melanocytes70,74,75. 
The role of type I interferon signaling in vitiligo pathogenesis is unclear. Vitiligo patients 
have an increased incidence of other type I interferon-driven autoimmune diseases, such 
as systemic lupus erythematous (SLE) and Sjogrens syndrome, and their association with 
vitiligo suggests an overlap in disease-associated pathways12,16,298,299. In addition, genome 
wide association studies identified variants in interferon-induced with helicase C domain 
1 (IFIH1) and toll like receptor adaptor molecule 1 (TICAM1) as vitiligo susceptibility 
loci40,300. Activation of IFIH1 or TICAM1 leads to induction of type I IFNs and 
expression of interferon-stimulated genes. Finally, both IFNγ and type I IFN receptor 
signaling can lead to activation of STAT1 homodimers to induce transcription of multiple 
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overlapping gene targets, including CXCL10, due to the sharing of promoter binding 
elements116,301. 
 
A few reports show a correlation between the presence of type I IFNs and vitiligo 
development. One study showed a modest increase in IFNB1 mRNA in vitiligo 
uninvolved skin compared to healthy control skin but there was no difference in gene 
expression compared to lesional skin 302. This suggests that the expression of type I IFN 
may be more closely associated with immune tolerance in the skin rather than progressive 
disease. Another study reported increased numbers of CD123 positive cells in the skin of 
vitiligo patients and moderately increased levels of CXCL9 and MxA, and concluded that 
type I IFN was responsible for this induction77,303, although these markers can also be 
associated with IFNγ. Furthermore, multiple case studies have reported the development 
of vitiligo in Hepatitis C Virus patients following therapy with PEG-IFNα and ribavirin 
48-50. However, this rare phenomenon is not only linked to vitiligo but also to the 
development of other autoimmune diseases such as type I diabetes and SLE 304-306.  
 
Here, we sought to determine whether type I IFN plays a functional role in vitiligo. In 
this study, we used two different mouse models of human disease. The first model is 
dependent on activation of autoimmune T cells using a vaccinia virus vaccine. The 
second model is a novel mouse model that is dependent on adoptive transfer of bone 
marrow-derived dendritic cells to prime autoimmune T cells. We find that induction of 
vitiligo using vaccinia virus vaccine resulted in severe disease in IFNaR-deficient hosts 
because of vaccinia virus persistence and the subsequent hyperactivation of autoimmune 
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effector CD8+ T cells. Consistent with this observation, we determined that vaccination 
with vaccinia virus improved anti-tumor immunity against melanoma in IFNaR-deficient 
hosts compared to treatment in WT hosts. We show functional evidence that type I IFN is 
not required for vitiligo, since induction of vitiligo with antigen-pulsed dendritic cells 
resulted in similar disease development in both WT and IFNaR-deficient hosts. Our 
results further define the pathways responsible for vitiligo pathogenesis and will inform 
new therapies. These studies highlight the role of type I IFN in vaccine-induced adaptive 
immune responses and suggest targeting IFNaR to benefit vaccine efficacy during 
melanoma therapy. 
2.2: IFNaR-deficient hosts develop accelerated and severe virally-induced vitiligo 
compared to WT hosts 
	
To directly compare the relative contribution of type I and type II interferon signaling in 
vitiligo pathogenesis, we induced vitiligo in WT, IFNaR-deficient, and IFNGR-deficient 
hosts as previously described57. In brief, vitiligo was induced by adoptive cell transfer of 
naïve CD8+ T cells specific for the melanocyte protein premelanosome (PMEL) and these 
cells were activated by same day infection with recombinant vaccinia virus (VV) 
expressing their cognate antigen. Effector PMEL CD8+ T cells traffic to the skin to target 
melanocytes and hosts develop epidermal depigmentation on the ears, nose, footpads, and 
tail between 5-7 weeks after PMEL transfer57,307.  
Surprisingly, induction of vitiligo in IFNaR-deficient hosts led to enhanced disease 
compared to wildtype hosts and resulted in complete depigmentation at some skin sites 
(Figure 2.1A-D). This was in stark contrast to IFNGR-deficient hosts, which were 
protected from disease (Figure 2.1C-D) and had significantly reduced PMEL numbers in 
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the epidermis and dermis (Figure 2.2A-C), consistent with our previous studies that 
targeted IFNγ using an antibody57. In IFNaR-deficient hosts, depigmentation was 
accelerated, with severe disease visible by 5 weeks post vitiligo induction (Figure 2.1E). 
We next asked whether IFNaR signaling affects PMEL trafficking into the skin. PMEL 
number was slightly increased in the skin at week 3, but significantly increased at week 5 
post vitiligo induction in IFNaR-deficient mice (Figure 2.1F-G). The altered kinetics of 
PMEL infiltration into the skin of IFNaR-deficient mice correlate with the acceleration of 
vitiligo. These results suggest that in contrast to IFNGR signaling, IFNaR signaling is not 










































































































Figure 4.1: Type I interferon receptor-deficient mice develop accelerated and severe vitiligo. 
Representative images of mouse ears, nose, footpads, and tail 7 weeks post vitiligo induction 
for A) WT, B) IFNaR KO, and C) IFNGR KO hosts. D) Vitiligo score at 7 weeks post vitiligo 
induction. E) Vitiligo scores of WT (black) and IFNaR KO (grey) mice at weeks 3, 5 and 7 
pooled from 2 to 3 separate experiments; mean + standard deviation of the mean. Normalized 
number of PMEL in the footpad epidermis (F) and dermis (G) of WT and IFNaR KO mice at 






2.3: IFNaR signaling on host radioresistant cells is important for controlling disease 
development 
	
In wild type and IFNaR-deficient vitiligo hosts, transferred wild type PMELs can respond 
to type I IFNs. Since type I IFN signaling can directly enhance the proliferation and 
effector capabilities of CD8+ T cells 140,308, we asked whether type I IFNs acted directly 
on PMELs to mediate severe disease. To test this, we transferred wild-type or IFNaR-
deficient PMELs into wild type and IFNaR-deficient hosts. Whether the T cells were 
IFNaR-deficient or IFNaR-sufficient had no impact on the course of the disease (Figure 
2.3A-B). However, IFNaR expression on host cells played a critical role as both WT and 
IFNaR-deficient T cells into IFNaR-deficient hosts developed significantly more severe 
















































































































Figure 2.2: Significantly reduced PMEL numbers in the tail epidermis of IFNGR KO 
mice at 7 weeks post vitiligo induction. A) Epidermal (B) Dermal, and (C) inguinal 
lymph node PMEL numbers normalized to 10,000 live single cells. 
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that type I IFN signaling directly on autoreactive PMEL does not modulate disease 
severity.  
 
To determine whether IFNaR deficiency on host hematopoietic or radioresistant cells was 
required for enhanced vitiligo, we generated bone marrow chimeric mice by 
reconstituting lethally irradiated WT or IFNaR-deficient mice with WT or IFNaR-
deficient BM stem cells. Chimeric mice that lacked IFNaR on radioresistant cells 
(IFNaRRC) developed significantly more severe disease compared to wild type recipients 
(Figure 2.3C). IFNaR-deficiency in the hematopoietic cells had more modest effects 
(Figure 2.3C). There was increased PMEL trafficking to the epidermis and dermis of 
IFNaRRC mice at 3 weeks post vitiligo induction (Figure 2.3D-F). Thus, IFNaR 
deficiency on radioresistant cells is responsible for the accelerated migration of 
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Figure 2.3: IFNaR signaling on host radioresistant cells is important for controlling disease 
development. A) Representative mouse images at 7 weeks post vitiligo induction. B) Vitiligo scores at 
week 7 post vitiligo induction. C) Vitiligo scores of chimeric mice 7 weeks post vitiligo induction. 
Normalized PMEL numbers in the epidermis (D), dermis (E), and draining lymph node (F) of chimeric 





2.4: IFNaR-deficient mice have increased circulating CD44+ effector memory PMEL 
with enhanced effector function 
	
In addition to increased migration of PMEL into the skin of IFNaR-deficient mice, we 
observed significantly increased numbers of circulating PMEL in the skin draining lymph 
nodes and spleen of IFNaR-deficient hosts as early as 3 weeks after vitiligo induction 
(Figure 2.4A-B), and the number of T cells remained significantly increased relative to 
wild type mice for up to 7 weeks. Phenotypic analyses of circulating PMEL revealed a 
significant increase in effector memory, CD44+CD62L- PMEL in IFNaR-deficient host 
mice compared to WT (Figure 2.4C-D). Since recirculating memory PMEL are important 
in mediating melanocyte death in vitiligo mice 309, these results suggest that increased 




Figure 2.4: IFNaR-deficient mice have increased circulating CD44+ effector memory 
PMEL. Normalized PMEL numbers in the skin draining lymph nodes (A) and spleen (B) 
at weeks 3, 5, and 7 post vitiligo induction. C) Representative flow cytometry plots pre-
gated on PMEL showing CD44 and CD62L marker expression. D) Percent of 
CD44+CD62L- PMEL in the spleen of WT and IFNaR KO mice at weeks 3, 5, and 7 post 
vitiligo induction. 

























































































2.5: Increased PMEL function in IFNaR-deficient hosts leads to enhanced CXCL9 
and CXCL10 chemokine ligand expression. 
	
 We next asked whether PMEL in IFNaR-deficient hosts exhibited increased effector 
potential. Vitiligo was induced in mice and then tissue cell suspensions were stimulated 
with anti-CD3/CD28 overnight. Epidermal PMEL in IFNaR-deficient hosts produced 
significantly more TNFα and IFNγ compared to WT controls (Figure 2.5A-C). 
Importantly, poly functional TNFα+ IFNγ+ PMEL were significantly increased in the 
epidermis of IFNaR-deficient host mice (Figure 2.5B). This data demonstrates that 
enhanced severity of vitiligo in IFNaR-deficient mice results from increased PMEL 
function.  
 
The IFN-induced chemokine ligands CXCL9 and CXCL10 promote migration of 
CXCR3+ PMEL T cells into the skin to destroy melanocytes during vitiligo70,75. Because 
we observed increased IFNγ production by PMEL in IFNaR-deficient mice, we 
monitored CXCL9 and CXCL10 expression levels in the skin over the course of disease 
using reporter REX3 mice 79. We previously described that chemokine production by 
epidermal keratinocytes is important for disease progression74, and we found that 
epidermal keratinocyte expression of CXCL9 and CXCL10 was significantly higher in 
IFNaR-deficient mice compared to WT mice (Figure 2.5D-F), as well as production by 
dermal phagocytes. These results suggest that increased IFNγ production by PMEL in 
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IFNaR-deficient mice amplifies expression of the chemokines CXCL9 and CXCL10, 





































































































































































Figure 2.5: Increased PMEL function in IFNaR-deficient hosts leads to 
enhanced CXCL9 and CXCL10 chemokine ligand expression. A) 
Representative flow plots of IFNγ and TNFα production by PMEL following ex 
vivo stimulation with 5 ug/mL anti-CD3 and 2 ug/mL anti-CD28 in the epidermis 
and dermis of WT and IFNaR KO mice. Percentage of IFNγ+, and IFNγ+ TNFα+ 
PMEL in the epidermis (B) and dermis (C). D) CXCL9 and CXCL10 reporter 
expression by epidermal keratinocytes and dermal MHC II+ phagocytes in the ear 
skin of WT and IFNaR KO mice at week 3 post vitiligo induction. Percent 
CXCL10 single positive and CXCL9+CXCL10+ double positive keratinocytes (E) 




2.6: PMEL do not require IFNGR signaling to mediate disease.  
	
Previous work has established that IFNγ and downstream chemokine production is 
required for vitiligo pathogenesis, but the role of autocrine IFNRG signaling on effector 
CD8 T cells is unknown. Autocrine IFNGR signaling has been reported to enhance the 
differentiation and effector capabilities of CD8 T cells as is type I IFN310. Since IFNγ 
production in IFNaR-deficient hosts was increased compared to WT, we asked whether 
signaling through the IFNGR on PMEL was required for this phenotype. To test this, we 
induced vitiligo in WT or IFNaR-deficient hosts with WT or IFNGR-deficient PMELs. 
Results reveal that autocrine IFNGR signaling is not required for vitiligo induction in WT 
mice (Figure 2.6A). These results also reveal that enhanced IFNγ production by PMEL in 
IFNaR-deficient hosts is not contributing to PMEL function through autocrine IFNGR 
signaling (Figure 2.6A). There were not significant differences in PMEL numbers in the 
skin between groups (Figure 2.6B-C). Although, as we previously described, IFNaR-
deficient hosts have increased PMELs in the lymph nodes and spleen (Figure 2.6D-E). 
There was a significant difference in WT vs IFNGR-deficient PMEL number in the 
lymph node in IFNaR- deficient hosts, and this may suggest that autocrine IFNGR 
signaling regulates the CD8 T cell memory pool at this site, although more experiments 
need to be performed311 (Figure 2.6D).  
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2.7: Reduced expression of PD-1 and PD-L1 in IFNaR-deficient hosts 
	
Since type I IFNs induce expression of negative immune regulators such as programmed 
cell death-1 and programmed cell death ligand 1 (PD-L1), which act to suppress T cell 
immune responses312 145, we sought to determine whether inhibitory molecule expression 
was altered in IFNaR-deficient mice. Both the percentage of PD-1 expressing PMEL and 
the mean fluorescent intensity (MFI) of PD-1 was significantly reduced on PMELs in the 
epidermis and dermis of IFNaR-deficient hosts compared to wild type hosts (Figure 
2.7A-D). However, there was no difference in PD-1 expression on PMEL in the skin 
draining lymph nodes (Figure 2.7E). In addition, IFNaRRC chimeras revealed 
significantly reduced PD-1 expression on PMEL (Figure 2.8A-C). Examination of PD-L1 
on cross priming CD8⍺ dendritic cells revealed a significant reduction in IFNaR-deficient 






































































































































































































































































A B C D E
Figure 2.6: Autocrine IFNGR signaling on PMEL does not mediate severe disease in 
IFNaR-deficient hosts. A) Vitiligo scores week 7 after vitiligo induction. Effector CD8 
PMEL numbers normalized to live single cells in the epidermis (B) dermis (C) skin 
draining lymph node (D) and spleen (E).  
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in IFNaR-deficient mice may result from dysregulated inhibitory molecule expression on 
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Figure 2.7: Reduced expression of negative immune regulators in IFNaR-
deficient hosts. A) Representative flow plots of epidermal and dermal PD-1 
expression on PMEL in WT and IFNaR KO host mice. B) PD-1 MFI on PMEL in 
the skin epidermis and dermis. Each data point represents an individual animal; n = 
5 with 2-3 replicate experiments performed. Percentage of PD-1 on epidermal (C) 
dermal (D) and draining lymph node (E) PMEL at weeks 3, 5, and 7 post vitiligo 
induction pooled from 2 to 3 separate experiments; mean + standard deviation of 
the mean. F) PD-L1 expression by CD8a dendritic cells in the spleen of WT and 
IFNaR KO mice at week 3 post vitiligo induction. G) Representative histogram and 
quantification of PD-L1 expression as determined by flow cytometry on WT and 
IFNaR KO CD8a DCs at week 3 post vitiligo induction. Each data point represents 





2.8: IFNaR-deficient hosts display persistent vaccinia virus infection  
	
Early studies show that both type I IFN and IFNγ are required for defense against 
vaccinia virus as mice deficient for either IFNaR or IFNGR showed increased 
susceptibility to infection compared to wild type mice313. Although our mouse model of 
vitiligo is induced with a highly attenuated vaccinia virus strain and we inject virus-
specific CD8+ T cells (PMELs) into mice that have the capability to clear infected cells, 
we asked whether IFNaR-deficient mice had reduced viral clearance. IFNaR-deficient 
host mice had significantly increased viral loads in the ovary at 9 days and 3 weeks post-
infection compared to wild type hosts (Figure 2.9A), however, no virus was detected in 
WT BM WT IFNaR KO BM WT 






















































































































































































Figure 2.8: PD-1 expression by PMEL is significantly reduced in hosts lacking IFNaR on 
radioresistant cells. A) Representative flow cytometry plots of PD-1 expression on epidermal PMEL in 
chimeric mice. B) Percentage of PMEL expressing PD-1 in the epidermis and dermis of chimeric mice 
5 weeks post vitiligo induction. C) PD-1 MFI on PMEL in the epidermis and dermis of chimeric mice 5 
weeks post vitiligo induction. 
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the skin of wild type or IFNaR-deficient mice (Figure 2.9A). These results suggest that 
increased viral replication in IFNaR-deficient hosts may be responsible for increasing the 
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Figure 2.9:  IFNaR-deficient hosts display vaccinia virus persistence.  A) 
Vaccinia virus PFU in WT and IFNaR KO mouse ovaries and ear skin determined 
by plaque assay at day 9 and week 3 post infection. Each data point represents an 
individual animal, pooled from 2 separate experiments. 
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2.9: Development of vitiligo in mice using PMEL pulsed-dendritic cells to prime T 
cells in vivo instead of virus 
	
To determine whether IFNaR-mediated restraint of the autoimmune T cell response was a 
result of increased vaccinia virus replication, we developed a novel mouse model of 
vitiligo that is independent of induction with a vaccinia virus vaccine. In this model, 
vitiligo is induced by sublethal irradiation of Krt14-Kitl* host mice the day before 
adoptive T cell transfer. The following day, bone marrow derived dendritic cells 
(BMDCs) pulsed with PMEL peptide are co-transferred with PMEL CD8+ T cells into 
hosts (Figure 2.10A). Hosts are injected with rmIL-2 for the following 3 days to support 
PMEL CD8+ T cell engraftment (Figure 2.10A). Following induction of disease, hosts 
develop epidermal depigmentation on the nose, ears, footpads and tail, similar to vitiligo 
induced with a vaccinia viral vector (Figure 2.10B).  
To determine whether IFNγ signaling is also required for disease pathogenesis in BMDC-
induced vitiligo, we used IFNGR-deficient mice as hosts. Vitiligo induced in IFNGR-
deficient hosts with BMDC-PMEL showed protection from disease and a significant 
reduction of PMEL in the epidermis and dermis (Figure 2.10C-F). However, engraftment 
of PMEL was unaffected, as PMEL numbers were similar in the lymph node (Figure 
2.10F). These results reveal IFNγ as the shared pathogenic pathway in both BMDC-









2.10: Depletion of resident memory CD8 T cells using anti-CD122 antibody 
treatment in BMDC-PMEL induced vitiligo hosts stimulates repigmentation.  
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Figure 2.10:  Induction of vitiligo using BMDC-PMEL is IFNGR dependent and 
leads to epidermal depigmentation similar to vaccinia virus induced disease. A) 
Schematic of the experimental set up for induction of vitiligo in mice using peptide-
pulsed bone marrow derived dendritic cells (BMDCs). B) Representative mouse images 
showing spots of depigmentation of the ears, nose, footpads, and tail of WT mice 7 
weeks post vitiligo induction. C) Vitiligo mouse scores 7 weeks post vitiligo induction. 
Normalized PMEL numbers in the epidermis (D), dermis (E), and draining lymph node 
(F) 7 weeks post vitiligo induction. 
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Previous studies revealed that vitiligo mice and human vitiligo patients contain resident 
memory CD8 T cells (TRM) in the skin67,76,309,314 and that TRM play a role maintaining 
disease. Furthermore, mechanistic studies in the vaccinia virus induced mouse model 
revealed that treatment of mice targeting the survival factor IL-15 using anti-CD122 
antibody resulted in significant repigmentation of the skin and correlated with the 
depletion of TRM from the skin67. We sought to determine whether BMDC-PMEL 
induced vitiligo also generated a population of resident memory PMEL CD8 T cells. 
Studies reveal that at 7 weeks post vitiligo induction the majority of PMEL in the 
epidermis of WT hosts express the TRM markers CD69 and CD103 (Figure 2.11A-B). 
Preliminary data in BMDC-PMEL induced vitiligo mice suggests that treatment of mice 
with anti-CD122 antibody led to significant repigmentation of the skin compared to mice 
treated with PBS (Figure 2.11C). Treatment with anti-CD122 led to reduced numbers of 
PMEL in the epidermis and dermis as well as skin draining lymph nodes (Figure 2.11D-
F). More experiments need to be performed to determine whether PMEL numbers are 
significantly changed with treatment as in vaccinia virus induced vitiligo. However, 
collectively these studies validate the BMDC-PMEL model as a new model of vitiligo 




























































































































































































Figure 2.11:  Vitiligo induced with BMDC-PMEL leads to development of epidermal TRM, 
which upon depletion using anti-CD122 antibody reverses vitiligo. A) Representative flow 
cytometry plot of epidermal CD69 and CD103 expressing PMEL. B) Quantification of the 
percent CD69+CD103+ PMEL in the epidermis of WT mice. C) Percent tail pigment before 
and after PBS or anti-CD122 treatment using ImageJ analysis to quantify pigmentation. 
Normalized PMEL CD8 T cell numbers in the epidermis (D) dermis (E) and skin draining 




2.11: IFNaR-deficient hosts do not develop severe vitiligo when disease is induced by 
dendritic cells in the absence of vaccinia virus 
 
To determine the role of type I IFN in vitiligo using a mouse model independent of the 
vaccinia virus vaccine, we induced vitiligo using BMDC-PMEL in IFNaR-deficient and 
wild type hosts. Disease severity was comparable between the two groups, revealing that 
type I IFN is not required during the effector phase of vitiligo development or for disease 
progression (Figure 2.12A-D). These results demonstrate that the extent of disease 
activity exhibited by CD8+ PMEL effector cells in the vaccinia virus-induced model was 
directly linked to the viral induction phase of the disease. Delayed clearance of vaccinia 
virus in IFNaR-deficient mice extends the priming phase of the disease, possibly 
resulting in greater activation of the effector T cells through a variety of mechanisms. 
These studies further show that timing and balance of type I and type II interferons 








2.12: Vaccinia virus vaccine therapy in IFNaR-deficient mice significantly enhances 
the anti-tumor response to melanoma 
	
Our results reveal that type I IFN limits viral persistence and enhances the activation of 
anti-melanocyte T cells. Since vaccinia virus vectors have also been used to prime T cells 
for tumor vaccination immunotherapies 287,293,315,316, we decided to ask whether a similar 
loss of type I IFN would improve tumor control in a model of adoptive T cell therapy 
enhanced by vaccinia virus vaccine (Figure 2.13A). B16-F10 melanomas were injected 
into WT or IFNaR-deficient mice. Six to eight days after melanoma injection, mice were 
infected with recombinant vaccinia virus expressing gp100 in combination with adoptive 
transfer of PMEL CD8+ T cells (Figure 2.13A). IFNaR-deficient mice showed improved 
tumor control compared to wild type mice (Figure 2.13B-C). Significant reduction in 































































































































A B C D E
Figure 2.12: Induction of vitiligo using BMDCs led to similar disease development in WT and 
IFNaR-deficient hosts. A) Vitiligo mouse scores 7 weeks post vitiligo induction. Normalized PMEL 
numbers in the epidermis (B), dermis (C), draining lymph node (D) and spleen (E) 7 weeks post 
vitiligo induction. 
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infiltrating PMEL CD8+ T cells (Figure 2.13D) and a significant reduction in the 
expression of the immune checkpoint inhibitor PD-1 on PMEL T cells (Figure 2.13E-F). 
These results reveal that the absence of type I IFN during viral vaccination leads to a 
more robust anti-melanocyte CD8+ T cell response in both autoimmunity and melanoma 




2.13: Discussion  
	
Here we describe the role of type I IFN in vitiligo using two different mouse models of 
disease. We report that in contrast to IFNγ, type I IFN signaling is not required during the 
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Figure 2.13: Vaccinia virus vaccine therapy in IFNaR-deficient mice significantly 
enhances the anti-tumor response to melanoma. A) Schematic of the experimental 
design for treatment of B16-F10 melanomas in WT and IFNaR KO mice. B) Tumor 
volume post treatment in WT and IFNaR KO mice. C) Tumor weight 14 days after 
adoptive T cell and vaccinia virus vaccine treatment. D) Normalized tumor infiltrating 
PMEL numbers 14 days post treatment in WT and IFNaR KO host mice. E) Percentage 
of PD-1 positive PMEL in WT and IFNaR KO host tumors. F) PD-1 MFI on PMEL in 
WT and IFNaR KO host tumors. 
	 71	
effector phase of vitiligo development or progression in mice. These results are important 
to inform future therapies for vitiligo patients.  
Our results further reveal that administration of a vaccinia virus vaccine in IFNaR-
deficient mice led to enhanced priming of CD8+ T cells and development of more severe 
vitiligo than in IFNaR-sufficient hosts. Type I IFNs are critical for controlling virus 
infections, and we report that type I IFN signaling is necessary to control the replication 
of even an attenuated vaccinia virus strain.  
 
Type I IFNs can contribute to impaired host adaptive immune responses and viral 
persistence during chronic infections 145,317. Blockade of type I IFN during chronic 
LCMV and HIV reactivates the anti-viral CD8+ T cell response leading to clearance of 
the virus through reduction of PD-1 on T cells and PD-L1 on dendritic cells 145,317. 
Similar to these observations, we show that type I IFN signaling on radioresistant cells 
during vaccinia virus persistence limits T cell expansion and activation. Increased 
activation of T cells in IFNaR-deficient mice following vaccinia virus vaccine may result 
from prolonged antigen exposure, because of persistent antigen presentation. Studies 
reveal that the amount of antigen presented by DCs can increase the CD8 T cell 
response318. Therefore, increased antigen density may increase PMEL CD8 T cell 
responses in IFNaR deficient hosts. An alternative hypothesis may be that infection of 
DCs with VACV in WT and IFNaR deficient hosts led to differences in T cell activation. 
One report showed that infection of DCs with VACV induced DC apoptosis. As a result, 
VACV led to impaired T cell responses compared to DC infection with influenza319. 
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VACV infection of DCs and subsequent apoptosis may result from type I IFN signaling. 
Thus, enhanced vitiligo in IFNaR deficient hosts may result from reduced apoptosis of 
infected DCs compared to WT hosts. Persistent infection may also impact the regulatory 
activity of dendritic cells, as we observed reduced PD-L1 on the CD8α dendritic cells 
responsible for T cell priming.  
 
Previous clinical studies report that injection of type I IFN into the skin has induced local, 
and sometimes distant depigmentation consistent with vitiligo. These reports demonstrate 
that overexposure of the skin to increased doses of type I IFN are capable of promoting 
depigmentation, although this does not necessarily indicate that type I IFN plays a role in 
normal vitiligo pathogenesis and we show functional evidence that type I IFN is not 
required for disease. Thus, the reported development of autoimmunity following IFN 
treatment may be dependent on chronic infection or an individuals’ predisposition to 
autoimmunity. Administration of type I IFNs in the setting of chronic infection may lead 
to the activation of cross-reactive T cells that cause autoimmune pathology, or 
alternatively that type I IFN-induced inflammation in the right context can recruit 
autoreactive T cells into the skin, similar to Koebner phenomenon 320.  
 
The generation of a robust cytotoxic T lymphocyte (CTL) response against melanoma is 
critical for the success of immunotherapy. Similar to the immune-suppressive effects of 
type I IFN during chronic viral infections, negative effects of type I IFNs occur in cancer 
inflammation and can lead to resistance to treatment 321,322. After observing more severe 
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vitiligo in IFNaR-deficient hosts following administration of a vaccinia virus vaccine, we 
sought to determine whether stimulation of the anti-tumor response to melanoma could 
be enhanced in IFNaR-deficient mice. Our results demonstrate that in the absence of type 
I IFN signaling, adoptive CD8+ T cell therapy in combination with a vaccinia virus 
vaccine enhances the anti-melanoma response. 
 
 A major limitation to the use of viral vaccines in cancer immunotherapy has been their 
lack of immunogenicity 323. Our results suggest that blockade of type I IFNs during 
vaccinia virus administration can improve the immunogenicity of the vaccine, likely 
resulting from increased CD8+ T cell priming during vector persistence. Studies using 
oncolytic viruses for cancer immunotherapy have also reported benefits of blocking type 
I IFNs to increase infection and improve responses to therapy324. A recent study reported 
increased tumor regression after IFNaR blockade during oncolytic virus therapy in 
combination with adoptive T cell therapy in mice 325. Our findings suggest that blockade 
of IFNaR during vaccinia virus vaccine for cancer immunotherapy may enhance both 
immunogenicity and persistence of the vector, thus improving vaccine efficacy, and may 
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Dendritic cells bridge the gap between the innate and adaptive immune system because 
they continuously sample antigen within their environment and are responsible for 
maintaining immune homeostasis326. Infection with a pathogen or sterile inflammation 
can lead to PRR activation and induces DC maturation. DC maturation involves the 
upregulation of MHC molecules, increased formation of MHC-peptide complexes as well 
as the upregulation of the co-stimulatory molecules CD80, CD86, and CD40327. PRR 
activation also triggers production of pro-inflammatory cytokines and type I IFNs. 
Mature DCs then traffic to the lymphoid organs where they can prime naïve T cells to 
become activated. Therefore, DCs play an integral part in fine tuning the adaptive 
immune responses through modulating T cell differentiation and function. Naïve T cells 
require three signals to become activated; cognate peptide MHC-TCR interaction, co-
stimulation, and cytokines328. Differential cytokine production downstream of PRR 
activation in DCs can induce different T cell programs. For example, in humans Gram 
negative bacteria induces DC production of IL-12 but not gram positive bacteria329,330. 
Mycobacterium tuberculosis can induce DC production of IL-10331. IL-12 typically 
promotes Th1 responses whereas IL-10 inhibits Th1 responses, therefore differential PRR 
activation and the cytokine milieu is important for driving T cell immunity332.  
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The aberrant activation of PRRs has been implicated in driving autoimmune disease. One 
example of this is the recognition of immune complexes that contain self-nucleic acids in 
the endosome, which drives SLE 333,334. Specifically, self-nucleic acids released in the 
endosome can trigger endosomal TLRs such as TLR7 or TLR9 and induce pro-
inflammatory cytokines or type I IFN production335. STING activation has also been 
implicated in autoimmunity. TREX1 is an exonuclease that is responsible for digesting 
DNA in the cytosol. Without TREX1, cytosolic DNA can activate innate immune 
signaling pathways such as cGAS-STING. Genetic mutations in TREX1 cause the type I 
IFN autoimmune disease Aicardi-Goutières syndrome (AGS). Because DCs are critical in 
driving T cell responses and because a few PRRs and signaling adaptors (NLRP1, 
MDA5,TRIF) are associated with vitiligo susceptibility, we sought to investigate the 
roles of PRRs in activating T cells in vitiligo mice.  
 
To investigate the role of PRR activation in DCs, we used the BMDC-PMEL vitiligo 
model (Chapter 2) in which bone marrow derived dendritic cells (BMDCs) are pulsed 
with PMEL peptide and then co-adoptively transferred into SCF recipient mice with 
PMEL CD8 T cells. This model allows for the manipulation of BMDCs by using 
genetically altered mice as BMDC donors to investigate the role of different PRRs on 
generating PMEL T cell responses in vitiligo.  
3.2: BMDC accumulation in the skin tissue following transfer into host mice 
	
We first asked where transferred BMDCs accumulate following injection into WT SCF 
hosts. To test this, we used BMDCs from a congenic mouse strain expressing CD45.1. 
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CD45 is a protein tyrosine phosphatase expressed by all hematopoietic cells and wild 
type C57BL/6 mice normally carry the CD45.2 allele. Since our host SCF mice are on the 
C57BL/6 background strain, they also carry the CD45.2 allele. Therefore, we acquired 
CD45.1 expressing C57BL/6 mice from the Jackson Laboratory and isolated BMDCs 
from these recipients for transfer into SCF CD45.2 hosts. This allows for the tracking of 
CD45.1 positive cells following injection into CD45.2 hosts. We induced vitiligo as 
previously described (Ch.2). Briefly, CD45.2 WT SCF hosts were sublethally irradiated 
and the following day CD45.1 BMDC-PMEL and PMEL CD8 T cells were co-
transferred into hosts. Tissues were harvested and flow cytometry was used to detect 
CD45.1 BMDCs over time.  
CD45.1 BMDCs were not found in any tissue tested at early time points (Day 1 and 3) 
post injection into SCF hosts (data not shown). But interestingly, CD45.1 BMDCs can be 
detected in the epidermis and dermis of SCF hosts at day 7 post injection (Figure 3.1A-
B). CD45.2 BMDCs are also detected in the lymph nodes and spleen at this time point 
(Figure 3.1B). Additional studies in the lab reveal that BMDCs can be detected in the 
spleen and tumor microenvironment of C57BL/6 hosts up until day 20 post transfer 
(Keitaro Fukuda, manuscript submitted). In vitiligo, CD45.1 BMDCs are present in the 
skin even before the appearance of PMEL CD8 T cells (data not shown). This is of 
interest to our studies because it may suggest that transferred BMDCs can activate CD8 T 













































































Figure 3.1: Transferred WT-BMDCs traffic to the epidermis and dermis 
in SCF hosts. A) Representative flow cytometry plots of CD45+ BMDCs in 
the epidermis, dermis, and spleen of SCF host mice day 7 post transfer. B) 
Normalized BMDC numbers in host tissues at day 7 post transfer. Each dot 
represents an individual host mouse.  
	 79	
3.3: Autocrine type I IFN signaling on BMDCs is not required for vitiligo 
development 
	
Previous studies described in chapter 2 revealed that following BMDC-PMEL transfer, 
host IFNaR signaling is not required for vitiligo induction. However, type I IFNs are 
critical for the maturation of DCs through induction of antigen presentation, induction of 
co-stimulatory molecules, and mediating migration of DCs to the lymph node for priming 
of T cell immunity. Thus, we sought to determine whether autocrine IFNaR signaling 
was required on BMDCs to initiate PMEL CD8 T cell activation using this model. To test 
this, we induced vitiligo in WT hosts using either WT or IFNaR-deficient BMDCs. 
Induction of vitiligo with IFNaR-deficient BMDCs revealed comparable disease scores to 
mice induced with WT BMDCs (Figure 3.2A). Therefore, we can conclude that IFNaR 
signaling on BMDCs is not required for induction of PMEL CD8 T cells using this 
model. Interestingly, PMEL numbers in the epidermis and dermis where significantly 
increased with IFNaR-deficient BMDCs compared to WT-BMDCs (Figure 3.2B-C). 
There was no difference in PMEL numbers between groups in the lymph nodes or spleen 
(Figure 3.2D-E).  
Although these results suggest that BMDCs do not require IFNaR signaling to mediate 
stimulation of T cells, both the VACV and BMDC-induced vitiligo models use 
expression of their cognate antigen (gp100) to intentionally induce CD8 T cell activation. 
Thus, the effects of type I IFNs on the priming and activation of endogenous autoreactive 






Figure 3.2: IFNaR signaling on BMDCs is not required for induction of vitiligo in 
mice. A) Vitiligo score at week 7. Normalized PMEL CD8 T cell number in the 
epidermis (B) dermis (C) skin draining lymph node (D) and spleen (E) 7 weeks post 



























































































































































3.4: Transfer of mature BMDCs induces significantly enhanced vitiligo in mice  
	
As previously described in chapter 2 and in the previous figure, IFNaR signaling was not 
required on host cells or on BMDCs for vitiligo induction using BMDC-PMEL. 
However, this model may bypass the effects of innate immune activation and effects of 
type I IFN in enhancing T cell immunity. Because maturation of DCs following PRR 
activation is important for inducing T cell immunity and because type I IFNs play a 
critical role during this process, we sought to determine whether stimulation of BMDCs 
with a TLR ligand would affect vitiligo development in mice. To test this, we used a 
synthetic oligonucleotide that contains unmethylated CpG dinucleotides called CpG 
ODN1826. DNA containing CpG motifs are found at a significantly higher frequency in 
bacterial DNA compared to mammalian DNA and are the ligand that activates TLR996. 
Following bone marrow isolation and 8 days of culture with granulocyte macrophage 
colony stimulating factor (GM-CSF) and IL-4, BMDCs were peptide pulsed and either 
left untreated or treated with CpG ODN1826 (TLR9 ligand) for 1 hr. WT or TLR9 ligand 
stimulated BMDCs were used to induce vitiligo in WT or IFNaR KO hosts. Results 
reveal that stimulation of BMDCs with TLR9 agonist led to significantly increased 
vitiligo score (Figure 3.3A). This suggests that maturation of BMDCs following PRR 
activation can enhance the T cell response. The effects of mature BMDC transfer 
observed in WT hosts was ameliorated following transfer into IFNaR KO hosts (Figure 
3.3B), suggesting that IFNaR signaling on host cells is important for the potentiating 
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effects of TLR ligand stimulated BMDCs. Previous studies have shown that murine 
BMDCs express TLR9 and that stimulation by CpG induced expression of the 
costimulatory molecules CD86 and CD40 and induces high levels of the pro-
inflammatory cytokines IL-12, IL-6, TNFα and the chemokine ligand CXCL10336. TLR9 
stimulation also leads to type I IFN production by DCs. Therefore, TLR ligand 
stimulation of BMDCs may increase vitiligo through maturation of DCs including 
induction of co-stimulatory molecules, and production of cytokines that can enhance T 







3.5: Aim2-deficient BMDCs induce significantly enhanced vitiligo in mice.  
	
The activation of PRRs by tumor derived or self-DNA is a potent activator of adaptive 
immune responses. One example of this is the activation of cGAS-STING pathway by 
tumor derived DNA256. Studies show that the activation of STING in tumor DCs leads to 
a robust cytotoxic T lymphocyte response against tumor cells. However, less is known 
about the activation of other DNA sensors during this process. Absent in melanoma 2 
(Aim2) is one of many innate immune sensors that detect cytosolic DNA197. It can detect 


















































WT SCF hosts IFNaR KO SCF hostsA B
Figure 3.3: TLR9 ligand stimulation of BMDCs before transfer leads to increase disease 
development compared to unstimulated BMDCs. Vitiligo disease score at week 7 in WT 
SCF hosts (A) and IFNaR KO SCF hosts (B).  
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inflammasome assembly that activates caspases337. Activation of the Aim2 
inflammasome leads to the maturation and secretion of the cytokines IL-1β and IL-18. 
Evidence suggests that dysregulation of the Aim2 inflammasome can lead to the 
production of autoantibodies in a mouse model of lupus338.  
 
In a mouse model of melanoma in which adoptive T cell therapy using PMEL CD8 T 
cells and BMDC-PMEL vaccine is used to induce tumor regression, Dr. Fukuda revealed 
that Aim2 KO-BMDCs induced robust PMEL infiltration into the tumor, and showed 
improved tumor regression (manuscript submitted). We sought to test the role of DNA 
sensing by Aim2 on the CD8 T cell response to vitiligo. Induction of vitiligo in WT hosts 
using Aim2 KO BMDCs led to significantly enhanced vitiligo severity compared to 
induction with WT BMDCs (Figure 3.4A). Enhanced disease in hosts induced with Aim2 
KO-BMDCs correlated with significantly increased PMEL numbers in the epidermis and 
dermis compared to hosts induced with WT BMDCs (Figure 3.4B-C). There were only 
modest increases in PMEL numbers in the lymph node following induction with Aim2 






We became interested in better understanding how the activation of Aim2 regulates 
melanocyte specific T cell responses during vitiligo in mice. Previous work reported that 
























































































































































Figure 3.4: Aim2 KO BMDCs induce more severe vitiligo compared to WT 
BMDCs. A) Vitiligo disease score at week 7. Normalized PMEL CD8 T cell 
numbers in the epidermis (B) dermis (C) skin draining lymph node (D) and spleen 
(E) 7 weeks post vitiligo induction.  
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production compared to WT BMDCs339. Corrales et al reveal that activation of the 
STING signaling components TBK1 and IRF3 were increased in Aim2 KO BMDCs 
compared to WT, suggesting that Aim2 regulates STING activation. The authors suggest 
a mechanism by which activation of the Aim2 inflammasome and caspase-1 following 
DNA stimulation inhibits the STING pathway339. Based on this data, we hypothesized 
that Aim2 KO BMDCs enhance vitiligo through the upregulation of IFNβ and 
enhancement of signaling through the STING pathway as is described by previous work. 
Although autocrine IFNaR signaling was not required on BMDCs in our previous 
experiments, enhanced IFNβ produced by Aim2 KO BMDCs through STING activation 
may act directly on Aim2 KO BMDCs to further their maturation and this may be one 
explanation for the enhanced disease severity seen using Aim2 KO BMDCs.  
To test this hypothesis, we induced vitiligo in SCF hosts using WT, Aim2 KO, 
Aim2/IFNaR DKO, STING KO, and Aim2/STING DKO BMDCs. Our results reveal 
significantly increased disease scores when Aim2 KO-BMDCs are used to induce disease 
compared to WT-BMDCs as was observed in Figure 3.4 (Figure 3.5A). Interestingly, 
ablation of IFNaR or STING on Aim2 KO-BMDCs did not result in significantly reduced 
scores (Figure 3.5A). These results suggest that the potentiating effects of Aim2 KO-
BMDCs on vitiligo development are not a result of enhanced STING signaling and that 
STING signaling by BMDC-PMEL is not required for effector T cell stimulation in this 
model. Although disease scores in Aim2/IFNaR DKO-BMDCs were reduced compared 
to Aim2-KO, STING-KO, and Aim2/STING DKO-BMDCs, it did not reach statistical 
significance (Figure 3.5A). These results suggest that the enhanced vitiligo following 
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induction with Aim2 KO-BMDCs is not a result of autocrine IFNaR signaling, or that 
autocrine IFNaR signaling plays only a small role in potentiating disease by Aim2 KO-
BMDCs. There were no significant differences in PMEL CD8 T cell numbers in the skin 




Figure 3.5: Enhanced disease mediated by Aim2 KO-BMDCs is not a result of 
enhanced STING or IFNaR signaling. A) Vitiligo disease score at 7 weeks post 
induction. Normalized PMEL CD8 T cell numbers in the epidermis (B), dermis (C), skin 
draining lymph nodes (D), and spleen (E) 7 weeks post vitiligo induction. Each dot 
represents one individual animal and the data is representative of two separate 


























































































































































































































































































































































































3.6: CXCL10 production by BMDC-PMEL is not required for induction of T cell 
responses.   
	
Our lab has previously shown that the chemokines CXCL9 and CXCL10 are critical for 
vitiligo progression in mice and are enhanced in the skin of patients with vitiligo53,70. We 
have shown that chemokine production by keratinocytes is critical for initiating disease, 
as loss of STAT1 signaling in keratinocytes led to significantly reduced disease in mice74. 
Since Aim2 KO-BMDCs increase expression of CXCL10339, and because DCs can 
recruit CXCR3 expressing T cells into tumors260,261,we sought to determine whether 
CXCL10 production by Aim2 KO-BMDCs contributed to the phenotype we observed. To 
test this, we induced vitiligo in WT SCF hosts using WT, CXCL10 KO or 
Aim2/CXCL10 DKO BMDCs. Our results reveal that CXCL10 production by BMDC-
PMEL is not required for vitiligo induction and that enhanced vitiligo following transfer 
of Aim2 KO-BMDCs is not a result of increased CXCL10 expression (Figure 3.6A). 
Vitiligo disease scores were not significantly different between WT-BMDCs and 
CXCL10 KO-BMDCs (Figure 3.6A). Aim2/CXCL10 DKO BMDCs showed increased 
disease scores but it did not reach statistical significance as a result of low power and 
because of high vitiligo scores in WT-BMDC induced hosts (Figure 3.6A). There were 
no significant differences in PMEL CD8 T cell numbers in the skin or secondary 
lymphoid organs between WT-BMDC and experimental groups (Figure 3.6B-E). 
Because CXCL10 production by keratinocytes is critical for inducing migration of PMEL 
CD8 T cells into the skin to promote disease, these results suggest that CXCL10 by the 





Figure 3.6: CXCL10 by Aim2 KO BMDC-PMEL does not mediate enhanced 
vitiligo development. A) Vitiligo disease score at week 7. Normalized PMEL 
CD8 T cell numbers in the epidermis (B) dermis (C) skin draining lymph node 









































































































































































































3.7: The role of TLR adapters MyD88 and TRIF in mediating T cell responses 
against melanocytes in vitiligo.  
TLR adaptors are TIR domain-containing proteins that associate with TLRs and mediate 
downstream signaling340. TRIF is one of six known TLR adaptor molecules; MyD88, 
MAL, TRIF, TRAM, SARM, and BCAP. Specific adaptor molecule recruitment to TLRs 
can alter the downstream signaling pathways and immune responses generated following 
TLR activation. I will focus on the signaling pathways mediated by MyD88 and TRIF. 
Both MyD88 and TRIF activate MAPKs and IKKs to induce transcription factors such as 
NF-κB, and interferon regulatory factor (IRF) family members. All TLRs except for 
TLR3 use MyD88 for signaling but TRIF is required for gene induction downstream of 
TLR3341. TLR4 is a unique receptor in that it utilizes both MyD88 and TRIF for 
signaling342. While TRIF is recruited directly to TLR3 for signaling, TRIF is recruited 
indirectly to TLR4 by the adaptor TRAM343,344. The N-terminal domain of TRIF interacts 
with TBK1 and IKKi/IKKε leading to activation of IRF3106,345. The C-terminal domain of 
TRIF activates NF-κB  and apoptosis pathways346,347. TLR3 signaling through TRIF 
leads to the activation of IRF3 and induces expression of IFNβ. TLR4 can activate 
multiple downstream pathways, but signaling through TRIF leads to IFNβ production.  
Studies show the importance of TRIF in anti-viral defense in humans. Although TRIF 
mediated TLR3 is associated with defense against dsRNA viruses, it is also important for 
resistance against DNA viruses and ssRNA viruses348. TRIF has also recently been 
shown to interact directly with STING to mediate downstream signaling349.   
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Few studies have looked at the role of TRIF in autoimmunity. In a mouse model for 
experimental autoimmune encephalomyelitis (EAE), TRIF activation was reported to 
suppress disease350. Suppression of EAE was a result of the induction of endogenous 
IFNβ and CCL2350. Another report provides evidence for TRIF mediated suppression of 
autoimmunity in a model of STZ induced diabetes351. The authors reveal that TRIF 
deficiency in DCs leads to acceleration of disease. TRIF signaling was shown to protect 
against IL-17-dependent arthritis model352, possibly through the induction of type I IFNs 
known to suppress arthritis. TRIF has also been shown to play a role in tissue repair 
because it was required for clearance of axonal debris microglia353, and TRIF KO mice 
show delayed wound healing354,355.  
 
Interestingly, GWAS studies have identified TICAM1, the gene that encodes TRIF, as a 
risk allele for vitiligo. The functional role of TRIF in vitiligo pathogenesis remains 
unclear, but new insights from single cell RNA sequencing analysis of vitiligo patient 
skin revealed a significant enrichment of TICAM1 in lesional macrophages compared to 
healthy skin macrophages (Figure 3.7A). The violin plot in Figure 3.7 is graphing both 
the normalized expression of TICAM1 on a per cell basis (left y-axis) and the mean 
TICAM1 expression of all macrophages per skin type (right y-axis). The black dot 
represents the mean expression of TICAM1 in macrophages from blister fluid in healthy, 
non-lesional, and lesional skin (right y-axis), where the individual points are plotted using 
the left-y-axis and show individual cell TICAM1 expression. The majority of cells 
express very little TICAM1, as shown by points at the bottom of the graph. However, 
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there are cells that express high levels. Thus, for us to see the average mean expression 
per skin type, we plotted this using the scale on the right y-axis. You can interpret this 
graph to show you both the cell specific TICAM1 expression (left y-axis) and the mean 
expression of all macrophages per skin type shown by the black dot (right y-axis).  The 
right y-axis and mean expression is much lower because there are many macrophages 
that did not express TICAM1 or were below the detection limit of the scRNA seq data. 
Differential gene expression analysis was run using findDEgenes function which calls 
EdgeR. All genes with false discovery rate of < 0.1 and abs (logFC) > 0.5 were used. 
Using these statistical tests, macrophages in vitiligo lesional skin express significantly 





































Figure 3.7: TICAM1 transcripts are significantly enriched in macrophages in lesional skin 
compared to healthy individuals.  A) Violin plot of healthy (pink), non-lesional (green) and 
lesional (blue) of TICAM1 transcripts.  
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Because of the potential implications of TRIF signaling in mediating vitiligo 
development in human patients, we sought to determine the effects of TRIF signaling in 
dendritic cells on the development of vitiligo using the BMDC vitiligo mouse model. To 
test this, we induced vitiligo in WT SCF hosts using WT BMDCs or TRIF KO-BMDCs. 
Results reveal that induction of vitiligo with TRIF KO-BMDCs led to the development of 
increased (although not significant) vitiligo disease scores (Figure 3.8A). Although 
PMEL CD8 T cells numbers were not significantly increased in the skin tissues, PMEL 
numbers were trending towards increased when TRIF-KO BMDCs were used to induce 
disease compared to WT BMDCs (Figure 3.8B-C). There were no significant differences 



































































































































































Figure 3.8: TRIF KO-BMDCs induce slightly worse disease in WT SCF hosts 
compared to WT-BMDCs. A) Vitiligo scores at week 7. Normalized PMEL CD8 T 
cells numbers in the epidermis (B) dermis (C) skin draining lymph nodes (D) and 
spleen (E). Each data point represents one mouse, pooled from 2 separate 
experiments.  
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Because MyD88 mediates signaling downstream of all TLRs, except TLR3, and because 
TLR4 uses both MyD88 and TRIF signaling pathways, we sought to determine the effect 
of MyD88 signaling in BMDCs on vitiligo pathogenesis. We induced vitiligo in WT SCF 
hosts using either WT-BMDCs or MyD88-KO BMDCs. Results revealed no significant 
differences in disease score or PMEL CD8 T cell infiltration in the skin (Figure 3.9A-E). 
Interestingly, there was a trend towards reduced disease and reduced PMEL numbers in 
WT SCF hosts induced with MyD88-KO-BMDCs compared to WT-BMDCs. This 
observation led to the inverse phenotype mediated by TRIF-KO BMDCs, which resulted 








































































































































































Figure 3.9: MyD88 KO-BMDCs induce similar disease scores compared to WT-
BMDCs in WT SCF hosts. A) Vitiligo scores at week 7. Normalized PMEL CD8 
T cells numbers in the epidermis (B) dermis (C) skin draining lymph nodes (D) 




Our results are similar to observations reported in another recent study. The authors 
reported delayed onset of STZ induced diabetes in mice with MyD88 deficient myeloid 
cells351. Although diabetes development was similar between mice with TRIF deficient 
myeloid cells and WT mice, the immunoregulatory enzyme indoleamine 2,3-dioxygenase 
(IDO) was reduced in mice with TRIF deficient myeloid cells, and they observed a 
significant reduction in skin draining lymph node Tregs351. This is in contrast to mice 
with MyD88 deficient myeloid cells in which IDO expression was induced351. These 
results suggest that signaling through TRIF in DCs may induce pathways that suppress 
autoimmune development, whereas signaling through MyD88 does not. The role of 
MyD88 and TRIF in vitiligo development requires further investigation, but our 
preliminary results suggest that TRIF signaling may also act to induce negative regulators 
to suppress the autoimmune response.  
 
A possible explanation for why disease severity is increased when TRIF KO-BMDCs are 
used to induce vitiligo compared to WT-BMDCs could be attributed to cell death. TRIF 
can induce apoptosis through RIP, FADD, and caspase-8347. Following TLR ligand 
binding, TRIF interacts with RIP1 and through RIP3 can trigger cell death. Also, when 
caspase-8 is inhibited, TRIF can drive necroptosis356. Therefore, determining whether the 
survival of TRIF deficient BMDCs is altered compared to WT BMDCs may help explain 





Our studies discussed in this chapter focused on identifying where BMDCs accumulate 
following transfer into SCF hosts, and investigating the roles of PRR activation and 
downstream signaling in BMDCs on the development of vitiligo in mice. Our findings 
reveal that BMDCs are present in the skin epidermis and dermis at least 7 days post 
transfer in WT SCF hosts. Unpublished results from Dr. Fukuda also reveals that BMDC-
PMEL remain in the tumor and spleen in a model of B16F10 melanoma through day 20 
post transfer. Our results showing BMDC-PMEL in the epidermis and dermis following 
transfer into WT hosts suggests that transferred BMDC-PMEL may be able to sample 
antigen from the skin microenvironment. The activation of BMDC PRRs by DAMPs or 
PAMPs may lead to the upregulation of costimulatory molecules and proinflammatory 
cytokines, which may alter the T cell responses against melanocytes in vitiligo following 
PMEL antigen recognition327. Interestingly, BMDCs are present in the skin tissue of mice 
before any PMEL CD8 T cells arrive in the skin. This suggests that pro-inflammatory 
cytokines, or chemokines produced by transferred BMDCs may not only affect PMEL 
CD8 T cell function, but could also affect the migration of PMEL CD8 T cells into the 
host skin tissue. We hypothesize that BMDCs are acting in the skin tissue to modulate T 
cell responses because of our observation that PMEL CD8 T cell numbers are 
significantly different at the skin site, and remain unchanged or have more modest effects 
in the secondary lymphoid organs (Figure 3.2 and 3.4).  
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We investigated whether PRR activation of BMDCs before transfer unto hosts could 
affect the development of vitiligo compared to immature BMDCs. We used a TLR9 
ligand, a synthetic CpG oligonucleotide (ODN), to stimulate BMDCs before transfer into 
host mice357. Transfer of CpG ODN stimulated BMDCs significantly increased vitiligo 
disease score compared to unstimulated BMDCs. These results suggest that activation of 
PRRs in BMDCs can affect the PMEL CD8 T cell response and alter disease progression 
in vivo. All BMDCs are pulsed with PMEL peptide, so differences observed in vitiligo 
score may result from differences in surface MHC expression, but are not the result of 
differences in the ability of BMDCs to process antigen. IL-12 produced following CpG 
stimulation promotes Th1 responses through increasing IFNγ production in both CD4 and 
CD8 T cells157,358. Thus, this may be one explanation for enhanced disease development 
following stimulation by TLR9 ligand. However, it is still unclear where and when naïve 
PMEL CD8 T cells are activated following transfer into host mice. Thus, increased 
vitiligo disease score seen following induction with CpG stimulated BMDCs may result 
from activation in the secondary lymphoid organs or in the skin. The kinetics and 
duration of changes induced following CpG activation of BMDCs, such as co-stimulatory 
molecule expression or pro-inflammatory cytokine production, may impact the PMEL 
CD8 T cell response. For instance, it is not clear whether CpG stimulated BMDCs remain 
phenotypically stable following transfer or whether their phenotype is plastic and changes 
after transfer into host mice. 
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Since stimulation of TLR signaling in BMDCs led to clinical differences in vitiligo score, 
we investigated the role of the DNA sensors STING and Aim2 in vitiligo development. 
Dr. Fukuda’s studies in a mouse model of adoptive T cell therapy and DC vaccine for 
melanoma immunotherapy revealed improved tumor regression when Aim2- KO 
BMDCs were used compared to WT BMDCs as a result of enhanced PMEL migration 
into the tumor. In parallel to these studies, we revealed that induction of vitiligo using 
Aim2 KO-BMDCs led to significantly enhanced vitiligo compared to induction with WT 
BMDCs. Aim2 KO BMDCs express increased IFNβ, and CXCL10 as a result of 
increased STING signaling339,359. We hypothesized that increased IFNβ or CXCL10 
production by Aim2 KO BMDCs may increase disease in mice, as CXCL10 is critical for 
driving disease progression in mice70 and IFNβ, although not required for disease could 
impact the T cell response. However, induction of vitiligo using Aim2/STING DKO, 
Aim2/IFNaR DKO, and Aim2/CXCL10 DKO BMDCs did not reverse the phenotype 
observed using Aim2 KO BMDCs. Therefore, it is clear that the effects of Aim2 KO 
BMDCs are not mediated through the STING pathway. Ligand binding to Aim2 also 
promotes the formation of the Aim2 inflammasome protein complex, which is 
responsible for the processing and release of IL-1β and IL-18 through caspase-1 
activation337. We hypothesized that the processing and secretion of IL-1β and IL-18 by 
BMDCs may play a role in suppressing disease. Both IL-18 and IL-1β have been 
implicated in promoting regulatory T cell (Treg) responses, which are important for 
suppressing effector CD8 T cells in autoimmunity and in vitiligo360-362. In a model of 
asthma, IL-18 production by DCs acted directly on T cells to drive conversion into 
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Tregs363. In another study, IL-1 acted as a signal 3 cytokine to induce Treg expansion and 
differentiation364. Thus, one explanation for increased disease induced with Aim2 KO 
BMDCs is reduced Treg expansion and recruitment as a result of reduced IL-1β and IL-
18 (Keitaro Fukuda, unpublished) in Aim2 KO BMDCs. To determine whether 
recruitment or expansion of Tregs is reduced following induction of vitiligo with Aim2 
deficient BMDCs compared to WT BMDCs, we could perform Foxp3 staining or use 
Foxp3-GFP mice as hosts.  
 
Another explanation Aim2 KO BMDCs may be leading to increased disease score is 
through the chemokine ligand, CCL22. CCL22 production by DCs can recruit Tregs into 
the tumor microenvironment and type I IFN was reported to inhibit CCL22 
production365,366. Since Aim2 KO BMDCs produce increased levels of type I IFN, this 
may indirectly lead to enhanced disease by suppressing CCL22, reducing Treg migration 
into the skin of mice. Thus, although induction of vitiligo with Aim2/IFNaR DKO 
BMDC did not completely reverse the effects of Aim2 KO BMDCs, it did lead to 
reduced disease scores. Aim2 could also be suppressing disease through suppression of 
an unknown pathway, or antagonism of another cytosolic DNA sensor.  
 
Other questions that remain unanswered are whether BMDCs are being matured in vivo 
through PRR activation, what are the PRR ligands triggering transferred BMDCs in vivo, 
and where are transferred BMDCs being triggered by PRR ligands in vivo. One 
hypothesis is that BMDCs located in the skin microenvironment are sensing PAMPs, or 
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DAMPs at the skin site leading to differential priming or activation of effector PMEL 
CD8 T cells. Another possibility is that sublethal irradiation, which induces cell death 
and DAMPs, may lead to the activation of PRRs in transferred BMDCs after they pick up 
debris in host mice. More experiments are required to answer these questions and to 
better understand how BMDC KO cells can mediate clinical differences in vitiligo 








4.1: Uncovering signals involved in vitiligo pathogenesis 
	
Susceptibility of vitiligo is multifactorial and includes genetic, environmental, and 
stochastic factors that drive epidermal depigmentation (reviewed in ch.1)2. Previous 
studies reveal that IFNγ signaling and induction of the Th1 chemokine ligands CXCL9 
and CXCl0 drive vitiligo progression70,367. However, the role of type I IFNs in driving 
vitiligo progression is unclear. Current therapies for vitiligo have variable success for 
patients and are not durable. Although JAK inhibitors, which target the IFNγ pathway 
have had success for vitiligo patients368(ongoing clinical trials), these treatments are not 
FDA approved yet and are also not durable. A better understanding of additional signals 
driving disease as well as signals driving different stages of disease will lead to the 
development of better targeted and durable therapies.   
4.2: Innate immunity in vitiligo  
	
One theory that suggests a role for innate immunity in the initiation of disease is based on 
evidence that melanocytes from vitiligo patients have increased cellular stress and have 
increased sensitivity to exogenous stressors28-30. Cell stress can cause the release of 
damage associated molecular patterns (DAMPs) that are sensed by PRRs369. Activation 
of PRRs leads to induction of type I IFNs and other pro-inflammatory cytokines through 
activation of NF-κB. Inflammation induced through type I IFNs and other cytokines may 
drive CD8 T cells into the skin tissue to initiate depigmentation370. Type I IFNs also 
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induce maturation of dendritic cells371, which are responsible for the cross priming of 
CD8 T cells, and thus can induce adaptive autoimmune responses.  
Another reason to investigate the role of type I IFNs in vitiligo pathogenesis is that type I 
IFNs induce the transcription of hundreds of ISGs including the chemokine ligands 
CXCL9 and CXCL10121,301, which we previously identified as driving vitiligo 
progression and maintenance70. Therefore, IFNγ and type I IFNs may act synergistically 
to drive disease and we sought to determine whether type I IFNs were involved in vitiligo 
progression.  
4.3: Controversy over the role of type I IFNs in vitiligo 
	
Vitiligo is associated with multiple autoimmune diseases and studies reveal that overlap 
in genetic susceptibility loci such as HLA may contribute to this risk17,18. A few 
autoimmune diseases associated with vitiligo are type I IFN driven such as Sjogrens 
syndrome and SLE12,16. One may hypothesize that their association links type I IFN 
signaling to vitiligo pathogenesis. Although this is a possibility, vitiligo is also highly 
associated with autoimmune diseases that are not primarily type I IFN driven13,299. Thus, 
the association with other autoimmune diseases may result from other shared genetic 
susceptibility loci encoding immune proteins or from environmental triggers.  
 
Only one report has provided evidence of type I IFNs in the skin of vitiligo patients77. 
The authors performed immunohistochemistry staining of skin tissue from healthy and 
vitiligo patients using the markers MX1, a type I IFN stimulated gene, and CD123+ , 
often a marker for pDCs77. The study reveals an increase in MX1 and CD123 staining in 
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progressive vitiligo skin compared to healthy skin. CD123 staining was primarily 
observed in the dermis, which is not the location of disease, while MX1 staining was 
observed in the epidermis. Although an increase in staining was observed, this method is 
not very quantitative, and the differences between healthy and vitiligo patient skin were 
small. Therefore, further investigation is required to determine whether type I IFNs are 
involved in disease progression.  
 
Other evidence suggesting a pathogenic role of type I IFN in vitiligo development are 
case studies that report the development of vitiligo following PEGylated IFNα injection 
and ribavirin therapy in HCV patients48-50. Some patients developed vitiligo at the 
injection site, while others showed development of lesions at distant sites. However, this 
rare phenomenon is not only linked to vitiligo but also to the development of other 
autoimmune diseases such as type I diabetes and SLE304-306. Linkage of PEGylated IFN 
therapy with vitiligo, SLE, and Sjogrens also links chronic virus infection and type I IFN 
to the development of autoimmune disease. Thus, in a context dependent manner type I 
IFNs may initiate vitiligo during chronic infection, or may stimulate the ISGs CXCL9 
and CXCL10 in the skin to recruit potentially autoreactive CD8 T cells to initiate disease.  
4.4: Type I IFN is not required for vitiligo progression in mice 
	
Our results reveal that vitiligo development occurs independent of type I IFN signaling in 
mice using two different mechanisms to activate autoreactive cells. In the first model, 
VACV infection is used to activate transferred PMEL CD8 T cells to drive disease. In 
this model, IFNGR KO hosts were protected from disease but IFNaR KO hosts 
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developed severe disease. Further studies revealed that severe disease was a consequence 
of persistent VACV infection in IFNaR KO hosts. The role of persistent infection in 
triggering robust CD8 T cell responses against melanocytes will be discussed in section 
5.5. In the second model, bone marrow derived dendritic cells pulsed with PMEL peptide 
were used to activate transferred PMEL CD8 T cells. Our studies revealed no difference 
in vitiligo disease score in IFNaR KO hosts compared to WT hosts. Collectively this data 
suggests that type I IFN signaling does not act as the effector cytokine driving vitiligo 
progression following activation of autoreactive cells by their cognate antigen. These 
results confirm that IFNγ signaling and downstream transcription of the chemokine 
ligands CXCL9 and CXCL10 are necessary and sufficient to drive disease forward. 
These results support the development of therapies that target the IFNγ signaling 
pathway, and not type I IFN signaling.  
 
Since we intentionally activate transferred PMEL CD8 T cells using VACV or BMDCs 
expressing their cognate antigen, these mouse models test the role of type I IFNs during 
the effector phase of vitiligo development. Therefore, the role of type I IFNs during 
disease initiation requires further investigation.  
Monobenzone is a phenol known to stress melanocytes, that has led to the development 
of vitiligo in human patients372. One study reported that monobenzone induced 
melanocyte stress led to the release of exosomes and stimulated shedding of melanocyte 
antigens by inducing autophagy373. Release of exosomes and autophagy led to DC 
activation and induction of a potent T cell response toward melanoma cells in vitro373. 
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This study is the first to identify melanocyte DAMPs in the activation of T cells. We 
were also interested in this phenomenon and performed studies on mice. Topical 
monobenzone treatment in mice did not exacerbate vitiligo in SCF hosts (unpublished) 
and we did not see any aberrant T cell responses in treated mice. Thus, mouse 
melanocytes may not be susceptible to monobenzone induced stress. To ask questions 
about disease initiation through melanocyte stress in mice we could try other known cell 
stressors such as hydrogen peroxide. 
 
 Whether melanocyte stress and exosome release occurs in vitiligo patient skin remains 
unknown. Our lab uses suction blistering to analyze cells and proteins involved in the 
disease process in the skin. We can blister patients with “confetti vitiligo”, which is 
clinically active vitiligo skin. Confetti lesions are the closest we can get to the initiation 
of a depigmented lesion since patients do not come into the clinic until after vitiligo 
appears on their skin. Thus, capturing the initiation events in vitiligo patients is 
challenging. We are now using scRNA sequencing and proteomics analyses to better 
understand these processes. A deeper and closer look at innate immune proteins and gene 
expression induced during active disease may capture innate immune cells and proteins 
involved in the initiation of vitiligo. Our scRNA sequencing data has already revealed 
that macrophages in vitiligo patient skin express higher levels of innate immune signaling 
components, such as MX1 and TICAM1. Thus, we are hopeful that this data will pin 
point cell types or signaling pathways that are involved in disease initiation.  
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I believe the best way to determine whether innate immunity or type I IFNs are involved 
in the initiation of the autoimmune response in vitiligo is to perform in vitro co-culture 
experiments. Our lab is working hard to develop in vitro 3D skin cultures to model T cell 
infiltration into the skin and the killing of melanocytes. Using 3D skin, we can apply 
different stressors, such as Monobenzone or hair dyes, which also contain phenols, to 
stress human melanocytes. With the addition of autologous PBMCs, purified CD8 T cells 
or human DCs, we can model initiation events in vitiligo. Comparing melanocytes, T 
cells and DCs derived from healthy individuals and vitiligo patients will also provide 
insight into whether melanocytes are intrinsically different and stimulate different T cell 
responses. We can then measure innate immune activation through gene expression, 
ELISA, or proteomic studies. 3D skin modeling experiments are technically challenging 
and require much optimization but will provide incredible insight into the initiation of 
disease, as well as other aspects of vitiligo progression.  
4.5: Type I IFN signaling can lead to enhanced T cell responses 
	
Although vitiligo progressed in mice independent of type I IFN signaling, our results 
using BMDCs to activate PMEL CD8 T cells provides evidence that innate immune 
signals including type I IFN production may enhance disease progression and 
autoreactive T cell priming.  The first piece of evidence comes from our studies in which 
maturation of immature BMDCs following stimulation with a TLR9 ligand led to a 
significant increase in vitiligo disease score. We did not test the effects of TLR9 ligand 
stimulation on co-stimulatory molecule expression or cytokine production by BMDCs 
prior to transfer into WT hosts. However, previous studies have revealed that TLR9 
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ligand stimulation increases expression of the co-stimulatory molecules CD80 and CD86 
and induces expression of the pro-inflammatory cytokines IL-12, which drives Th1 
responses, as well as type I IFNs336. We tested whether type I IFN signaling by host cells 
was important for enhancing disease following TLR9 activation of BMDCs and reveal 
that type I IFNs do in fact play a role in increasing disease severity. Where transfer of 
TLR9 stimulated mature BMDCs induced enhanced disease in WT hosts, TLR9 
stimulated mature BMDCs transferred into IFNaR KO hosts did not result in significantly 
enhanced disease. Therefore, type I IFN signaling is partially responsible for enhanced T 
cell activation and vitiligo development following TLR9 stimulation. The other piece of 
evidence that suggests type I IFNs play a role in potentiating disease is from our studies 
revealing that Aim2 KO BMDCs induce significantly increased vitiligo compared to WT 
BMDCs. We show that this phenotypic effect is not a result of signaling through STING, 
or through CXCL10, but we do observe reduced scores when Aim2/IFNaR DKO 
BMDCs are used to induce disease. Although this effect was not statistically significant, 
it suggests that enhanced disease in hosts induced with Aim2 KO BMDCs is partly a 
result of autocrine IFNaR signaling.  
Our studies answered two important questions. First, we revealed functional evidence 
that vitiligo progression occurs independently of type I IFN signaling. Second, we 
provide evidence for the role of type I IFN signaling in enhancing vitiligo development 
and autoreactive T cell activation by DCs during T cell priming.  
4.6: Persistent or chronic infection may trigger activation of melanocyte specific T 
cells leading to vitiligo 
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Genetic susceptibility to vitiligo is only a piece of the overall risk for vitiligo 
development. This suggests that environmental factors including infection can be a 
trigger for disease. Viral triggers of vitiligo remain unclear, but multiple viruses are 
associated with the development of other autoimmune diseases374. Interestingly, vitiligo 
development has been associated with two chronic infections, HCV and HIV (discussed 
in Ch. 1) 44,49. Molecular mimicry, bystander activation of autoreactive cells, and epitope 
spreading are a few mechanisms by which viral infection may trigger autoreactive 
immune responses375. Molecular mimicry is the idea that T cells specific for foreign 
antigens can cross react against self-antigens. It is widely accepted that a single T cell can 
respond to various distinct peptides and that the MHC-peptide complexes can trigger 
cross-reactivity by the same TCR. This bystander activation of autoreactive cells by DCs 
can occur following infection with a virus375. Epitope spreading is the idea that priming 
of the immune response to a specific antigen spreads to initiate activation of cells specific 
for a different portion of the same protein or to a different protein375. This phenomenon 
could be beneficial for viral infections and for stimulating immune responses against 
tumors, however, it is detrimental when it results in activation of self-reactive T cells. It 
remains plausible that chronic infection with HCV or HIV can lead to the activation of 
melanocyte-reactive CD8 T cells through mechanisms described above and result in 
vitiligo development, although this has not been studied. In HCV, cases describing 
vitiligo development occur following injection with type I IFN. Type I IFNs act to mature 
DCs and enhance cross-presentation, so this may result in the activation of melanocyte-
reactive cells in these patients. In HIV, the presence of the chronic virus is associated 
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with vitiligo, and treatment reverses vitiligo. Thus, in these cases epitope spreading may 
result in vitiligo.   
 
Previous studies report that the precursor frequency of T cells specific for a certain 
pathogen are high and studies estimate that a naïve mouse has around 14,000 T cells 
specific for VACV376,377. We did not investigate the role of bystander CD8 T cell 
activation in the development of severe vitiligo in IFNaR KO hosts. However, activation 
of bystander VACV specific CD8 T cells during persistent VACV infection in IFNaR 
KO hosts may have contributed to disease development.  
 
Interestingly, most viruses associated with autoimmunity are viruses that establish 
chronic infection. This suggests that immune dysregulation associated with chronic 
infection leads to autoimmunity. Chronic infection can lead to aberrant activation of 
PRRs and production of pro-inflammatory cytokines. Pro-inflammatory cytokines not 
only lead to maturation of DCs, which may present unwanted antigens to T cells, but also 
can lead to recruitment of cross-reactive T cells into a peripheral tissue, leading to 
initiation of autoimmunity.  
 
4.7: Effects of type I IFN signaling on vitiligo is complex 
	
Collectively our results suggest that vitiligo progresses independent of type I IFN 
signaling (Chapter 2), but that production of type I IFNs and type I IFN signaling during 
T cell activation can enhance disease development (Chapter 3). We also provide evidence 
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that type I IFNs may have significant direct effects on the residence of CD8 T cells and 
thus impact the maintenance of vitiligo (Appendix A). Following intradermal injection of 
IFNβ, we show that CD69, an early T cell activation marker and marker of resident 
memory CD8 T cells was significantly upregulated (3 fold). This may explain why 
treatment with IFN in HCV patients could trigger autoimmunity. For instance, type I 
IFNs can induce the recruitment of potentially autoreactive cells into the skin of patients 
through induction of the chemokine ligands CXCL9 and CXCL10, while also 
upregulating markers of tissue residence leading to vitiligo development. Our studies in 
mice reveal that type I IFN is not required for the effector phase of vitiligo, but the role of 
type I IFN in human vitiligo is still unclear. Interestingly, multiple immune genes 
identified by GWAS as vitiligo susceptibility genes include innate immune signaling 
proteins. The identified innate immune TLR adaptor, TICAM1 (TRIF), is associated with 
vitiligo and is also significantly upregulated in vitiligo lesional skin by scRNA 
sequencing. We investigated the functional role of TRIF on vitiligo development in mice 
(Ch. 3)378. It is unclear whether the association of these innate immune risk alleles such 
as TICAM1 are linked to type I IFN production, apoptosis, or other signals that are 
induced downstream. Therefore, examination of human patient samples for the activation 
of innate immune molecules will be important to determine their role in disease and we 
have the tools to perform these studies using blister fluid or in vitro 3D skin models.  
Macrophages and dendritic cells, which are critical innate immune cells triggered by 
DAMPs and PAMPs are located in the skin dermis. Optimizing blister fluid to capture 
more of these cell types in our analyses may help identify innate immune signals driving 
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human disease. Blistering patients earlier during the course of their disease, such as a 
newly developed lesion, may help catch the role of innate immunity in the initiation of 
disease.  
	
4.8: Increasing viral vaccine therapy with interferon blockade 
	
As reviewed in Chapter 1, VACV has been used in pre-clinical and clinical studies for the 
use in the treatment of metastatic melanoma and has increased CTL responses but overall 
did not have significant effects on overall survival of patients, or only some patients 
responded to treatment279. VACV vaccines for melanoma are continuing to be developed. 
Interferon adjuvant therapy for melanoma was also not successful in clinical trials, 
despite its robust stimulatory role in generating CTL responses in pre-clinical studies, and 
it was shown to have high toxicity262,270,271. To test the effects of type I IFN signaling 
during VACV vaccine therapy, we infected WT or IFNaR KO hosts with recombinant 
VACV in combination with adoptive PMEL CD8 T cell therapy. Treatment led to 
significant increases in tumor infiltrating PMEL CD8 T cells in IFNaR KO hosts 
compared to WT hosts. Expression of PD-1 on PMEL CD8 T cells was reduced in IFNaR 
KO hosts suggesting enhanced cytotoxic ability, and we observed improved tumor 
regression in IFNaR KO hosts compared with WT hosts. One explanation for this effect 
is prolonged antigen exposure as a result of persistent VACV in IFNaR KO mice. Live 
VACV vaccines have been used in the clinic for treatment of melanoma with relatively 
minimal side effects and were well tolerated283. Thus, blocking type I IFN following 
administration of VACV vaccine may enhance the persistence of the vector, prolonging 
the CTL response, and leading to increased or complete responses in melanoma patients. 
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Another possibility for why blocking type I IFN may be beneficial is that VACV, which 
has a broad cellular tropism, can also infect tumor cells379. Tumor cells often down 
regulate IFNaR signaling, which allows for their unrestrained growth380. However, this is 
advantageous for VACV, and increases its ability to replicate in tumor cells. Therefore, 
blockade of type I IFN during VACV therapy may in fact increase its replication in 
cancer cells, lead to activation of DCs by tumor derived DNA, and increase recruitment 
of CD8 T cells into the tumor. Finally, type I IFNs can induce immunosuppressive 
cytokine production such as IL-10, which has been shown to limit VACV spread381. This 
may dampen the CTL response, along with induction of PD-1 and PD-L1, which limit T 
cell responses. It is of interest to determine whether VACV vaccine and adoptive T cell 
therapy in combination with PD-1 blockade will have synergistic effects. 
Some believe that a major limitation to current recombinant viral vaccines is that it 
induces strong T cell responses to the viral epitopes and not the recombinant tumor 
derived antigen epitopes. Dissection of a clinical trial in which an attenuated strain of 
vaccinia virus expressing melanoma associated antigens revealed that the vaccine 
generated a cytotoxic T lymphocyte (CTL) response that was dominated by VACV viral 
specific responses instead of responses specific for the recombinant protein MelanA382.  
Thus the effectiveness of the vaccine to induce T cell responses against the tumor 
associated antigen MelanA is blunted as a result of robust T cell responses against the 
viral antigens323. An alternative thought it that the generation of T cell responses to the 
virus may lead to antigen spreading or activation of cross-reactive T cells that actually 
increase the anti-tumor response. Generating anti-viral CD8 T cells following VACV 
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vaccine administration would especially be beneficial when an oncolytic or tumor 
targeting VACV vaccine is used because these anti-viral cells would destroy tumor cells. 
Because blockade of type I IFN resulted in persistent infection following rVACV 
vaccine, generation of endogenous anti-viral CD8 T cells may have contributed to the 
anti-tumor response seen in IFNaR deficient host mice.  
Multiple studies have shown that immunotherapies are often combined with 
cyclophosphamide, a lymphodepletion regime that induces type I IFN production. This 
can lead to the upregulation of MHC class I, which can help aid in the anti-tumor 
response but also be detrimental if the activation of CTLs leads to activation of cross-
reactive cells and subsequent autoimmunity or other off-target toxicities. Therefore, 
blocking type I IFN following viral vaccine therapy combined with adoptive T cell 
therapy may minimize off target consequences of the vaccine.  
 
Type I IFN production by tumor derived DCs has been shown to be critical in the priming 
of anti-tumor CD8 T cells. However, we believe that in the context of administration of a 
viral vaccine expressing tumor derived antigens, blockade of type I IFN is beneficial. 
Blockade of type I IFN overcomes the suppressive mechanisms of the tumor 
microenvironment through reducing PD-1 and PD-L1 upregulation that would normally 
occur following viral infection through type I IFN. We observed that type I IFN signaling 
was not required for the priming and the anti-tumor response against melanoma following 
vaccinia virus vaccine. This may be virus specific, as CD8 T cells do not require type I 
IFN signaling to mediate the anti-viral response and clearance of VACV.  Whether this 
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would hold true for other viruses in which CD8 T cells do require type I IFN is unclear. 
More pre-clinical studies need to be performed to determine whether blockade of type I 
IFN may be beneficial. We are now performing experiments using an anti-IFNaR 
antibody in combination with VACV vaccine and adoptive T cell therapy. The timing of 
type I IFN blockade is an important question that needs to be addressed. A major concern 
in implementing treatment with IFN blockade with a vaccinia virus vaccine is whether 
blockade of type I IFN would lead to dissemination of VACV and how this may effect 
immunocompromised individuals.  
 
4.9: Final thoughts and conclusions 
	
Our results provide mechanistic insight into the role of type I IFNs in vitiligo and we 
reveal that their role in disease is complex. Type I IFNs are not required for the effector 
phase of disease in mice, however, their production during T cell activation led to 
significantly enhanced disease severity in mice. Type I IFNs produced during T cell 
activation may result from the activation of PRRs from DAMPs or pathogen infections 
and our studies provide evidence for environmental insults or innate immune activation in 
driving effector T cell responses in vitiligo.  
 
Our results also offer evidence that combined VACV vaccine and adoptive T cell therapy 
induces robust CTL responses in hosts lacking IFNaR and suggest that IFNaR blockade 
during treatment has synergistic effects that overcome regulatory mechanisms of tumor 
suppression. IFNaR blockade may not only increase viral vector persistence but increase 
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immunogenicity. Because vitiligo and melanoma are strongly linked, our results also 
reveal that IFNaR blockade, which leads to improved tumor regression may induce 
vitiligo due to the robust CD8 T cell response. Although this is an adverse effect of 
treatment, vitiligo development has been shown to have significant benefits for 
melanoma patients. Melanoma patients have improved survival outcomes. Based on 
studies in mice, generation of melanocyte/melanoma resident memory T cells following 
vitiligo development after melanoma immunotherapy may protect against future disease 
relapse. Therefore, these studies provide critical insights into the use of IFNaR blockade 













All mice were maintained in pathogen-free facilities at UMMS, and procedures were 
approved by the UMMS Institutional Animal Care and Use Committee and in accordance 
with the NIH Guide for the Care and Use of Laboratory Animals. The following mouse 
strains were used for these studies and are available from The Jackson Laboratory: PMEL 
TCR transgenic mice (stock no. 005023), KRT14-Kitl*4XTG2Bjl (Krt14-Kitl*) mice 
(stock no. 009687), IFNgR1-deficient mice (stock no. 003288), CXCL10-deficient mice 
(stock no. 006087) and IFNaR1-deficient mice (provided by A. Rothstein, now available 
as stock no. 032045, MMRRC). Aim2-deficient mice of C57BL/6 background were 
obtained from Genentech. Sting-deficient mice were kindly provided by Dr. D. Stetson 
(University of Washington) and backcrossed for more than 10 generations at the UMMS. 
Aim2-deficient mice were intercrossed with Sting-deficient, IFNaR-deficient, or Cxcl10-
deficient mice to produce Aim2/Sting DKO, Aim2/IFNaR DKO, and Aim2/Cxcl10 DKO 
mice. All mice used for vitiligo studies were on a C57BL/6J background, or a mixed 129-
B6 background that had been backcrossed for at least 10 generations. Age and sex-
matched mice were used, and both male and female mice of all strains were tested to 
avoid gender bias. 
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Vitiligo induction using vaccinia virus 
	
Vitiligo was induced as previously described307,367. Briefly, PMEL CD8+ T cells were 
isolated from the spleens of PMEL TCR transgenic mice through negative selection on 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the 
manufacturer’s instructions. Purified CD8+ T cells (1×106) were injected intravenously 
into sublethally irradiated (500 rads 1 day before transfer) Krt14-Kitl* hosts. Recipient 
mice also received i.p. injection of 1×106 pfu rVV-hPMEL (N Restifo, NCI, NIH) on the 
same day of transfer. Scoring of vitiligo progression in mice was done by a blinded 
investigator, using a point scale based on the estimated depigmentation on the ears, nose, 
tail, and footpads. Replicate experiments were performed at least twice.  
Generation of BMDCs for peptide-pulsed DC vaccine 
	
Bone marrow-derived dendritic cells (BMDCs) were generated according to a modified 
version of a previously described method 383,384. Briefly, bone marrow cells isolated from 
the femurs and tibia of 7–14-week-old mice were filtered through a 70-µm nylon strainer, 
red blood cells lysed by ACK lysis buffer (Sigma Aldrich), and cultured in BMDC 
medium (RPMI-1640 containing 10% FBS, 100 U/mL PS, 2 mM L-glutamine (Gibco), 
50 µM 2-mercaptoethanol (Sigma Aldrich), 20 ng/mL GM-CSF (PeproTech), and 10 
ng/mL IL-4 (PeproTech)). The BMDC medium was replaced on days 3 and 6. On day 8, 
non-adherent cells were harvested and BMDC purity was assessed by flow cytometry to 
ensure staining for markers CD11c, MHC II, CD11b, and CD86. For BMDC vaccination, 
non-adherent cells were pulsed for 3 h at 37°C with 10 µM of the human gp10025–33 
(hgp100) peptide (GenScript) in Opti-MEM media (Gibco) and washed three times with 
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PBS before their use. For induction of vitiligo in mice, 1.0x106 CD11c+MHC II+ hgp100 
pulsed BMDCs were co-injected intravenously into sublethally irradiated (500 rads, 1 day 
before transfer) WT, IFNaR-deficient or IFNGR-deficient hosts.  
Bone marrow chimeras 
	
Bone marrow was isolated from femurs and tibias of donor mice. Recipient mice were 
lethally irradiated (800 rads at least 5h before transplant) and administered 5x106 bone 
marrow cells intravenously. Mice were left untreated for 8 weeks for reconstitution of 
bone marrow cells prior to use in the vitiligo model.  
B16F10 Tumor Model  
	
The murine melanoma B16F10 cell line was obtained from ATCC. B16F10 cells were 
cultured in DMEM (Corning) supplemented with 10% fetal bovine serum (FBS) and 100 
U/ml penicillin/streptomycin (PS). B16F10 cells were profiled at passage 4-9 to prevent 
heterogeneity introduced by long-term culture. B16F10 cells were confirmed negative for 
Mycoplasma species by RAPIDMAP-21 (Taconic Biosciences) and were maintained at 
37°C in a humidified atmosphere of 5% CO2.  
For use in melanoma immunotherapy experiments, B16F10 melanoma cells (1.0x105) 
were resuspended in 100 µL of PBS and implanted subcutaneously into the right flank of 
6–12-week-old WT and IFNaR deficient mice. Tumor size was measured in two 
dimensions by caliper and is expressed as the product of two perpendicular diameters. 
PMEL CD8 T cells were isolated from the spleens of PMEL TCR transgenic mice 
through negative selection on microbeads (Miltenyi Biotec) according to the 
manufacturer’s instructions. After 6-8 days of tumor injection, purified PMELs (1.0 x106) 
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were transferred by intravenous injection into sublethally irradiated (500 rad, day -1) 
hosts. On the same day mice were infected with 106 pfu of rVV-hPMEL to activate 
PMEL in vivo. 
Plaque Assay 
	
The day before infection, CV-1 cells were seeded in a 6 well plate at 1 million cells/well 
in 2 mLs DMEM + 10% fetal bovine serum (FBS) and incubated at 37°C overnight. The 
following day, serial dilutions of virus infected tissue supernatants or viral stock control 
was performed. Culture medium was removed from CV-1 cells and 600 ul-1mL of virus 
infected tissue supernatant was added to each well and incubated at 37°C for 1 hour. 
After incubation, 2 mLs of a heated agarose solution containing 0.6% agarose and 2X 
MEM+20% FBS mixed at 1:1 was added to each well. Plates were incubated at 37°C for 
72 hours. Cells were fixed by adding 1.5 mLs of 10% formaldehyde. Following fixation, 
excess fixative and agar was removed carefully to avoid scraping the plate underneath. 
Cells were then stained with 200 ul of 2% Crystal violet diluted in water.  
Flow Cytometry 
	
Tissues were harvested at the indicated times and processed as previously described307. 
Skin was incubated for 1 hour at 37°C in 5U/mL of Dispase II (Roche, Basel, 
Switzerland) for tail or 50U/mL Dispase II for ears or footpad skin. Epidermal skin was 
removed and mechanically dissociated into a single cell suspension for staining. Dermis 
was incubated in 1mg/mL collagenase IV (1 mg/ml; Roche) and 2 mg/mL DNAse I 
(Sigma Aldrich, St. Louis, MO) for 1 hour at 37°C before mechanical dissociation. All 
murine flow cytometry cell suspensions were blocked with 2.4G2 (Bio X Cell) following 
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staining with antibodies. Tissue staining with Live Dead Blue (1:1000 Invitrogen) and 
relevant cell surface antibodies was performed at 4°C for 30 minutes. Subsequently, cells 
were washed one and then fixed with either Cytofix/Cytoperm solution (BD 
Biosciences). Fixed cells were either washed twice with Perm/Wash Buffer (BD 
Biosciences) or incubated for 20 minutes in Perm/Wash before intracellular staining. For 
intracellular staining, relevant antibodies diluted in Perm/Wash Buffer (BD Biosciences) 
were applied to fixed cells and incubated for 30 minutes at 4°C.  Intracellular staining of 
Foxp3 was performed using the Foxp3/Transcription Factor Staining kit (eBioscience) 
after surface staining. For intracellular cytokine staining, tissue supernatants were 
incubated overnight with plate bound anti-CD3ε (5 µg/ml) and soluble anti-CD28 (2 
µg/ml) in the presence of Brefeldin A (Biolegend) for 3-4 hrs before staining with 
antibodies against cell surface and intracellular markers. Data was collected with the LSR 
II or Cytek Aurora and analyzed with FlowJo software.  
Blister Induction and Processing 
	
Suction blisters (1 cm in diameter) were induced on the skin using the Negative Pressure 
Instrument Model NP-4 (Electronic Diversities, Finksburg MD). Suction chambers were 
applied to the skin with 10-15 mm Hg of negative pressure and a constant temperature of 
40°C. Usually blisters form between 30-60 minutes after initiation of the procedure but 
this varies depending on the skin site and disease state. After blister formation the 
interstitial fluid is aspirated through the roof using a 1 ml insulin syringe (28 gauge). The 
interstitial fluid is pelleted at 300 x g for 10 minutes. The supernatant can be collected 
and frozen for future analysis by ELISA. The cell pellet can be analyzed by staining with 
	 125	
antibodies for flow cytometry.  
ELISA 
	
Levels of CCL20 from blister interstitial fluid was quantified per the manufacturer’s 
instructions (R&D- DY360-05). Optical densities were measured using a Perkins Elmer 
Envision 2102 multilabel reader and used to calculate concentrations using a 4-parameter 
logarithmic standard curve using GraphPad Prism.  
Statistical Analyses 
	
Statistical analyses were performed using GraphPad Prism software (GraphPad, La Jolla, 
CA). Dual comparisons were made with unpaired Student’s t test. Groups of three or 
more were analyzed by analysis of variance with Tukey or Dunnett posttests. P values 








ADDITIONAL EFFECTS OF TYPE I INTERFERON ON VITILIGO 
DEVELOPMENT 
 
A.1: Do neutrophils play a role in vitiligo development?  
	
Neutrophils are granulocytes that are found in the blood and are early responders to 
infection. Neutrophils have also been shown to play a role in mediating inflammation in 
many diseases, cancer and autoimmunity385. Neutrophils traffic to different parts of the 
body through chemokine gradients and specifically express the chemokine receptor 
CXCR2 allowing for migration into tissues secreting the ligands CXCL1 and CXCL2. 
Type I interferons suppress the expression of these chemokine ligands. One study showed 
that influenza induced type I IFN production suppressed CXCL1 and CXCL2, leading to 
improved survival from secondary challenge with bacterial pneumonia386. Another study 
found that endogenous type I IFNs actively suppress the production of CXCL1 and 
CXCL2, and IFNβ deficient mice had increased neutrophil recruitment into tumors and 
significantly enhanced CXCL1 and CXCL2 levels387.  Type I interferon production by 
epithelial cells can suppress the recruitment of neutrophils through CXCL1 and 
CXCL2388. CXCL2 was significantly upregulated in the skin of mice following HSV-1 
infection and type I IFNs ameliorated expression in the ganglia and to a lesser extent in 
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the skin388. These studies suggest that type I IFN mediated regulation of the chemokines 
CXCL1 and CXCL2 may be important to suppress skin inflammation.  
  
Expression of these chemokine ligands not only drives migration of neutrophils into 
tissues, but any CXCR2 expressing cell. It was reported that expression of the human 
homologue of CXCL1/2 known as IL-8 can induce trans-endothelial migration of human 
skin homing T cells389. Other papers suggest that IL-8 responsive CD8 T cells have an 
effector phenotype and enhanced cytotoxic ability390,391. Therefore, expression of these 
chemokine ligands in skin could also enhance CD8 T cell migration and function in 
vitiligo.   
 
Nanostring, a technology that involves the direct detection of RNA transcripts was 
performed on WT and IFNaR KO vitiligo mouse ears to determine differential gene 
expression at week 7 post vitiligo induction. Preliminary results showed that the 
chemokine ligands CXCL1 and CXCL2 were significantly upregulated in IFNaR KO 
vitiligo hosts compared to WT (Figure A.1A-B). This data corroborates previous reports 
that type I IFN suppresses these chemokine ligands. CXCL1 and CXCL2 were also 
upregulated in the skin of bone marrow chimera hosts that lacked IFNaR on 
radioresistant cells (Figure A.1A-B). The upregulation of CXCL1 was confirmed by 
qPCR at week 7 post vitiligo induction (Figure A.1C) but the upregulation of CXCL2 
was not significantly upregulated (Figure A.1D). These results suggest that severe disease 
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development in IFNaR KO hosts compared to WT may be a result of increased 
expression of these chemokine ligands in skin.  
 
 
To determine whether neutrophils were recruited to the skin during vitiligo in mice and 






































































































































































Figure A.1: Chemokine ligands CXCL1 and CXCL2 are upregulated in IFNaR KO 
hosts compared to WT hosts. A) CXCL1 and (B) CXCL2 transcripts in the ear skin 
of naïve, WT and IFNaR vitiligo mice performed using Nanostring Technologies. C) 
CXCL1 and (D) CXCL2 transcripts by qPCR of ear skin of WT and IFNaR KO mice 
at weeks 3, 5, and 7 post vitiligo induction.  
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neutrophil recruitment we performed flow cytometry. Detection of neutrophils in skin 
was determined by CD11b and Ly6G co-expression. Results revealed that neutrophils are 
recruited to the skin of vitiligo mice but in small numbers (Figure A.2A-C). Numbers of 
neutrophils in the epidermis increase from week 3 to week 5 in WT and IFNaR KO hosts 
(Figure A.2A-C). However, we found no differences in neutrophil numbers in the skin 
between WT and IFNaR KO hosts (Figure A.2A-C). These results conclude that 
increased skin CXCL1 and CXCL2 in IFNaR KO hosts did not alter neutrophil migration 







A.2: Do CXCR2 ligands CXCL1 and CXCL2 affect PMEL CD8 T cells during 
vitiligo in IFNaR KO hosts? 
	
Because previous studies report the role of CXCL1 and CXCL2 chemokine ligands in the 
migration and function of effector CD8 T cells389-391, we sought to determine their effect 
on PMEL CD8 T cells in vitiligo. We hypothesized that increased numbers and function 
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Figure A.2: Neutrophil recruitment to the skin is unaltered in IFNaR KO hosts 
compared to WT hosts. A) Representative flow cytometry plots of CD11b+ Ly6G+ 
neutrophils in the epidermis of mice at weeks 3, 5, and 7 after vitiligo induction. Number 
of neutrophils in the (B) epidermis and (C) dermis of mice at weeks 3, 5, and 7 after 
vitiligo induction.  
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of PMEL in IFNaR KO hosts may result from the upregulation of skin CXCL1 and 
CXCL2 in IFNaR KO hosts. We tested this by inducing vitiligo in WT and IFNaR KO 
hosts with WT PMEL or CXCR2-deficient PMEL, the receptor for CXCL1 and CXCL2. 
Results reveal that CXCR2 signaling on PMEL is not required for disease in mice and is 
not responsible for the enhanced disease seen in IFNaR KO hosts (Figure A.3A). Results 
did reveal a significant reduction in CXCR2-deficient PMEL numbers in the epidermis 
and dermis compared to WT PMEL in WT hosts (Figure A.2B-C). These results suggests 
that CXCL1 and CXCL2 may also mediate recruitment of PMEL into the skin during 
vitiligo. Competition experiments need to be performed in order to determine whether 
CXCR2-deficient PMEL are disadvantaged in their recruitment to the skin compared to 
WT PMEL. However, CXCR2 signaling on PMEL is dispensable for disease 
development since the PMEL that did navigate into the skin tissue were able to cause 
disease comparable to WT PMEL (Figure A.3A). These results also confirm that CXCL1 
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Figure A.3: PMEL do not require CXCR2 signaling to mediate vitiligo in mice. A) 
Vitiligo score at week 7. Normalized PMEL numbers in the epidermis (B) dermis (C) 




A.3: Does treatment of mice with exogenous interferon affect vitiligo progression? 
	
Multiple case studies have reported that PEGylated IFNα treatment for HCV patients 
correlated with development of vitiligo48,49. Since type I IFNs stimulate many adaptive 
immune responses, it suggests that excess type I IFNs may drive vitiligo pathogenesis. To 
model this is mice, we injected mice subcutaneously (s.c.) with 10,000 IU of IFNα or 
IFNβ. To avoid affecting the anti-viral response to VACV, we waited to treat WT hosts 
until VACV is cleared, which is about 10 days. Systemic delivery of IFNα or IFNβ 
resulted in comparable vitiligo disease score to untreated hosts (Figure A.4A). PMEL 
numbers were also comparable between IFN treated and untreated WT hosts (A.4B-E). 
These result suggest that the presence of excess IFN does not lead to enhanced vitiligo in 















































































































Figure A.4: Systemic type I IFN therapy did not induce more severe disease in WT 
SCF hosts. A) Vitiligo disease score 7 weeks post vitiligo induction. Normalized PMEL 
CD8 T cell numbers in the epidermis (B), dermis (C), skin draining lymph nodes (D), and 
spleen (E).  
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To model PEGylated IFN injection for HCV patients, and to determine whether type I 
IFNs injected directly into the skin tissue could induce severe disease in hosts pre-
disposed to vitiligo through PMEL transfer, we injected PBS, or IFNβ intradermally into 
WT hosts. Preliminary results revealed no significant difference in vitiligo score or 
PMEL number in the skin (Figure A.5A-D). However, epidermal and dermal PMEL 
numbers were slightly increased following IFNβ treatment and additional studies are 
required to determine whether local IFN injection enhances PMEL retention or survival 
in the skin. An interesting observation was that IFNβ significantly induced (3 fold) the 
expression of CD69 on PMEL CD8 T cells in the epidermis and dermis (Figure A.5E-G). 
A study reported by Shiow et al. identified the mechanism of CD69 upregulation 
following type I IFN392. They revealed that CD69 was upregulated following type I IFNs 
and that CD69 negatively regulates S1P1 to promote lymphoid retention392. Our previous 
work shows that resident memory CD8 T cells, that co-express CD69 and CD103 are 
critical in promoting vitiligo maintenance67,309. Therefore, although preliminary results 
reveal that IFNβ treatment didn’t enhance development of vitiligo during the effector 
phase of disease, type I IFN treatment may drive vitiligo maintenance through the 
upregulation of CD69 and retention of melanocyte-reactive CD8 T cells in the skin. 
Increased expression of CD69 may also explain the increased PMEL numbers in the skin 
tissue in IFNβ treated hosts. Treatment of vitiligo hosts exhibiting stable disease with 































































































































Figure A.5: Local IFNβ  injection into skin leads to robust induction of CD69 on CD8+ 
PMEL. A) Vitiligo score of WT and IFNβ treated mice at 7 weeks. Normalized PMEL 
CD8 T cell number in the epidermis (B) dermis (C) and skin draining lymph node (D). E) 
Representative flow cytometry plots of CD69 and CD103 expression on skin PMEL from 
WT and IFNβ treated mice. Representative histograms (F) and mean fluorescent intensity 
(G) of CD69 on skin PMEL from WT and IFNβ treated mice.   
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A.4: Is regulatory T cell recruitment different in WT and IFNaR KO hosts? 
 
Regulatory T cells are a subset of T cells that express the transcription factor Foxp3 and 
are responsible for maintaining peripheral tolerance to self. Studies suggest that Tregs 
play a role in suppressing melanocyte-specific CD8 T cells responses in vitiligo360,361. 
The ratio of CD4 to CD8 T cells in the blood are reduced in vitiligo patients compared to 
healthy controls361. Evidence also supports that Treg suppression of CD8 T cell 
proliferation and cytolytic function is significantly reduced in vitiligo patients compared 
to healthy individuals360. In mouse models of vitiligo, the overexpression of CCL22 in 
the skin, a chemokine attractant for Tregs, led to enhanced Treg number in the skin and 
significantly reduced depigmentation365.  Another study, which adoptively transferred 
Tregs into host mice and treated hosts with rapamycin, led to lasting remission of 
vitiligo393. Unpublished studies in our lab showed that Tregs are critical for the 
suppression of vitiligo in our mouse model (Kingsley Essien Thesis). These studies 
suggest that an imbalance of Treg number or Treg dysfunction may lead to vitiligo 
development and that Tregs play a critical role in suppressing melanocyte-specific CD8 T 
cells. Because IFNaR- deficient mice developed such severe disease and Tregs suppress 
disease in our mouse model, we asked whether there was a difference in Treg numbers 
compared to WT hosts. We analyzed Treg numbers by flow cytometry using either a 
Foxp3-GFP reporter mice or by intracellular staining of Foxp3. Our results reveal that 
Tregs are not significantly reduced in the skin of IFNaR KO hosts compared to WT hosts 
following induction of vitiligo using VACV at either week 3 or 5 (Figure A.6A,C,E,G). 
Numbers of PMEL CD8 T cells are significantly increased in IFNaR KO hosts as 
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previously described in chapter 2 (Figure A.6B and F). At 3 weeks post vitiligo induction 
Treg numbers are slightly increased in IFNaR KO hosts compared to WT (Figure A.6C). 
Thus, Treg recruitment to the skin in IFNaR deficient hosts is similar to WT hosts. 
However, as a result of the increased PMEL numbers in IFNaR deficient hosts compared 
to WT hosts, the Treg/PMEL ratio is significantly lower in IFNaR deficient hosts at 
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Figure A.6: Tregs are recruited into the epidermis at equal numbers in IFNaR 
deficient hosts compared to WT hosts.	A) Representative flow cytometry plots of 
epidermal Tregs by intracellular staining with Foxp3 at week 3 post vitiligo induction. B) 
Normalized PMEL numbers in the skin epidermis at week 3. C) Normalized Treg 
numbers in the epidermis at week 3. D) Treg/PMEL ratio in the skin epidermis at week 3. 
E) Representative flow cytometry plots of epidermal Tregs using Foxp3-GFP mice at 
week 5 post vitiligo induction. F) Normalized PMEL numbers in the skin epidermis at 
week 5. G) Normalized Treg numbers in the epidermis at week 5. H) Treg/PMEL ratio in 
the skin epidermis at week 5. 
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PREFACE TO APPENDIX B 
 
Appendix B contains original text, which represents the unpublished work of Rebecca L. 
Riding and Mitchell Thorn (Pfizer Inc.) and is currently prepared for submission. 
Rebecca L. Riding performed the experiments, analyzed data, and co-wrote and critically 
reviewed the manuscript with Mitchell Thorn. Dr. James Strassner, Dr. Zainab Abbas, 
Dr. Maggi Ahmed, and Evangeline Kim performed blistering experiments. Wei Li 
designed experiments. Dr. John E. Harris designed experiments and critically reviewed 




STABILIZATION AND IMMUNOPHENOTYPING OF T CELLS ISOLATED 
FROM BLISTER FLUID OF PSORIATIC LESIONS 
 
 
B.1: Stabilization of blister fluid cells using TransFix preserves immunophenotyping 
markers.  
	
Psoriasis is a chronic auto-inflammatory disease that primarily affects the skin and joints 
and is mediated by T cells394,395. Pathogenesis is multifactorial but is marked by 
infiltration of Th17 cells that drive inflammation at the skin site and studies show that 
IFNγ may promote this recuritment396,397. Although advancements in targeted psoriasis 
therapies are available, the tools to assess treatment efficacy in a clinical trial setting are 
limited. Clinical trials of psoriasis therapies require information-rich assays that can 
assess multiple parameters relevant to drug activity, including PK/PD, target engagement, 
efficacy, inflammation status of the affected tissue and cellular composition of healthy 
and lesional areas of skin. Flow cytometry is a powerful tool that can simultaneously 
assess the sizes of T cell subsets and the expression of biomarkers associated with 
psoriasis. In this study we sought to assess the feasibility of evaluating T cells isolated 
from blister fluid of psoriatic skin lesions by flow cytometry. Blistering is performed by 
inducing negative pressure and heat to the skin for a brief period of time. The interstitial 
fluid that collects within each blister contains immune cells and proteins that may be 
important during the local inflammatory response53. Blister induction and immune-
phenotyping of cells present in blister fluid is not only a valuable basic science tool, but 
also has potential to be an important tool for investigating immune biomarkers for 
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dermatological diseases because blistering is rapid, painless, and non-scaring. The link 
between elevated Th17 cells present in the skin and development of psoriasis further 
suggests that blister fluid cell analysis may be an important component of clinical trials 
that evaluate psoriasis therapies397.  
 
Sample stability including cell viability and biomarker stability are important 
considerations for clinical assays when shipping from the clinical to analytical site is 
required. This is a particular challenge for flow cytometry assays because, typically, 
samples collected at the clinical site are shipped to the analytical laboratory, necessitating 
sample stability for 24 hours or longer. In this study we observed that the frequency of 
viable blister fluid cells decreased significantly from 64% at 2hrs post collection to 43% 
at 6 hrs post collection (Figure B.1A). Therefore, we tested a commercial cell stabilizer, 
TransFix, to preserve the sample while retaining the cellular markers used in our T cell 
immunophenotyping panel. The panel includes markers for CD4 and CD8 cells as well as 
markers for the chemokine receptors expressed by Th1 and Th17 cells. We performed 
flow cytometry analyses of fresh PBMC and blister fluid cells compared to cells 
preserved in TransFix for 24 hrs. The C-C motif chemokine receptor 6 (CCR6) is highly 
expressed on Th17 cells that are abundant in psoriasis lesion infiltrates and play an 
important role in psoriasis pathogenesis398. Therefore, detection of CCR6, CCR4 and the 
chemokine receptor CXCR3, expressed by Th1 cells were analyzed. Comparison between 
CD4 and CD8 T cells from fresh and TransFix stabilized blister fluid is shown in Figure 
B.1. Both CD4 and CD8 T cell subsets are abundant in psoriatic lesions. While some 
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patients had equal ratios of CD4 and CD8 T cells in the blister fluid, others had 
predominantly CD4 T cells (Figure B.1B-D). CD4 and CD8 T cells within psoriasis 
patient blister fluid were predominantly Th17 by expression of CCR6, but we also 
detected CD4 and CD8 T cells expressing phenotypic markers for Th1-17 cells by co-
expression of CCR6 and CXCR3 (Figure B.1C-D). Importantly, the frequency and cell 




























































































































Figure B.1: TransFix stabilization of blister fluid cells in psoriasis patient lesions. A) 
Cell viability of blister fluid cells fresh or 6 hrs post collection. B) Representative flow 
cytometry plots of fresh and TransFix blister fluid samples showing CD4 and CD8 T 
cells and chemokine expression. C) Frequency of the cell population from the parent gate 






B.2: Analysis of blister fluid from psoriasis patients may be used for evaluation of 
clinical responses to treatment  
	
It is now clear that patient blood is a poor indicator of disease state in peripheral tissues 
such as the skin. We performed paired immunophenotyping analyses of psoriasis patient 
PBMCs and blister fluid cells. We find significant differences in the immunophenotype 
of CD4+ and CD8+ T cells in psoriasis patient blood compared to blister fluid (Figure 
B.2A-D). The majority of CD4+ and CD8+ T cells in psoriasis patient skin are CD45RA- 
and represent mature memory T cells. In the blood, the majority of CD4+ T are neither 
Th17, Th1-17 or Th1, whereas in the skin, CD4+ T cells are predominantly Th17 marked 
by expression of CCR6 (Figure B.2A-B). We also detect a population of CD4+ T cells in 
blister fluid that express both CCR6 and CXCR3, a chemokine receptor expressed by Th1 
cells and refer to these cells as Th1-17. These cells like Th17 are highly enriched in 
psoriasis skin compared to the blood (Figure B.2A-B). Another finding shared by the 
majority of psoriasis patients tested is that while CD4+ CCR6/CCR4 co-expression was 
modest in peripheral blood, the majority of CD4+ T cells in the skin co-express CCR6 
and CCR4 (Figure B.2A-B). CD8+ T cells in the skin of psoriatic lesions also adapt a 
Th17 phenotype including a subset of Th1-Th17 cells present, which are enriched in 
psoriasis skin compared to blood (Figure B.2C-D). Similar to CD4+ T cells, CD8+ T cells 
in the blood are not CCR6/CCR4 double positive but the majority of CD8+ T cells in 
lesional skin do co-express CCR6 and CCR4 (Figure B.2C-D).  
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To determine whether CCR6 ligand, CCL20, is increased in psoriasis patient skin 
compared to the skin of healthy individuals, we performed ELISA on the blister fluid 
supernatant. Results show an increase in CCL20 in psoriasis lesional skin compared to 























Our results reveal that blister fluid sample stabilization using TransFix preserves T cell 
infiltrates for clinical analyses. Our results also reveal a significant enrichment of Th17 
and Th1-17 cells in psoriasis lesions, which are not detected in the blood of patients. Our 
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Figure B.2: Elevated Th17 and CCR4-CCR6 co-expressing CD4 and CD8 T cells in 
psoriatic lesions compared to blood. A) Representative flow cytometry plots comparing 
the phenotype of CD4 and CD8 T cells in PBMCs and lesional blister fluid from 
psoriasis patients. B) Quantification of the frequencies of CD4 T cell subsets in the blood 
and blister fluid. C) Quantification of the frequencies of CD8 T cell subsets in PBMCs 
and lesional blister fluid. D) ELISA of CCL20 levels in the blister fluid of healthy 
individuals compared to lesional psoriasis skin.  
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results further suggest that the infiltration of Th17 and Th1-17 cells in psoriasis lesional 
skin can be used to predict successful treatment responses during clinical trials and that 
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